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Band 4.1B is a cytoskeletal adaptor protein that regulates various cellular behavior;
however, the mechanisms by which Band 4.1B contributes to intracellular signaling
are unclear. This project addresses in vivo and in vitro functions for Band 4.1B in
integrin-mediated cell adhesion and signaling. Band 4.1B has been shown to bind to
β8 integrin, although cooperative functions of these two proteins have not been
determined. Here, functional links between β8 integrin and Band 4.1B were
investigated using gene knockout strategies. Ablation of β8 integrin and Band 4.1B
genes resulted in impaired cardiac morphogenesis, leading to embryonic lethality by
E11.5. These embryos displayed malformation of the outflow tract that was likely
linked to abnormal regulation of cardiac neural crest migration. These data indicate
the importance of cooperative signaling between β8 integrin and Band 4.1B in
cardiac development. The involvement of Band 4.1B in integrin-mediated cell
adhesion and signaling was further demonstrated by studying its functional roles in
vitro. Band 4.1B is highly expressed in the brain, but its signaling in astrocytes is not
understood. Here, Band 4.1B was shown to promote cell spreading likely by
interacting with β1 integrin via its band 4.1, ezrin, radixin, and moesin (FERM)
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domain in cell adhesions. In astrocytes, both Band 4.1B and β1 integrin were
expressed in cell-ECM contact sites during early cell spreading. Exogenous
expression of Band 4.1B, especially its FERM domain, enhanced cell spreading on
fibronectin, an ECM ligand for β1 integrin. However, the increased cell spreading
was prohibited by blocking β1 integrin. These findings suggest that Band 4.1B is
crucial for early adhesion assembly and/or signaling that are mediated by β1
integrin. Collectively, this study was the first to establish Band 4.1B as a modulator
of integrin-mediated adhesion and signaling.
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Chapter 1. Introduction
1.1. Cell migration
Cell migration and invasion are crucial for numerous physiological and
pathological events, such as embryogenesis, tissue repair, immune response,
vascular diseases, and cancer (Costa and Parsons 2010; Nowotschin and
Hadjantonakis, 2010; Peri F, 2010; Caswell et al., 2008). Characterizing regulatory
signaling pathways of cell motility, therefore, is pivotal to understanding human
physiology and pathology. The regulation of cell motility requires the complex
coordination of cell-extracellular matrix (ECM) interactions and cytoskeleton
organization (Teckchandani et al., 2009).
Adherent cells first begin to migrate by forming protrusions termed
lamellipodia and filopodia (Le Clainche and Carlier, 2008). These protrusions are
stabilized by adhesions that connect the ECM to the cytoskeleton (Hood and
Cheresh, 2002). Integrin cell adhesion receptors are essential for orchestrating
adhesion formation, cytoskeleton organization, and cell polarity during migration
and invasion (Ridely et al., 2003). After binding to ECM ligands, integrins recruit
and/or interact with multiple adaptors and signaling molecules, such as α-actinin,
focal adhesion kinase (FAK), tensin, and talin, which in turn bind to actin-binding
vinculin and paxillin (Zamir and Geiger, 2001; Calderwood et al., 2000). At the
adhesion sites, integrins provide traction for the cell body to move forward by linking
the ECM to the cytoskeleton, and also function as mechanosensors that can alter
cytoskeletal dynamics (Webb et al., 2002). During migration, adhesions are
disassembled at both leading and trailing edges, and integrins are actively recycled.
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Proteases degrade various ECM components, including fibronectin, laminin, and
collagen (Friedl and Wolf, 2003). Some proteases, such as seprase, MMP1, MMP2,
MT1-MMP directly bind to integrins (Dumin et al., 2001; Ellerbroek et al., 2001;
Galvez et al., 2002). These processes allow for dynamic regulation of cell’s forward
motion and new protrusion formation (Ridely et al., 2003) (Figure 1). Invasion also
involves adhesion formation, proteolysis of ECM components, and cell movement,
although it requires penetration of tissue barriers by cells (Friedl and Wolf, 2003).
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Figure 1. Cell migration.
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Figure 1. Cell migration.
Cell migration begins with the formation of lamellipodia. Focal adhesions that
connect the ECM to the cytoskeleton stabilize these protrusions. At the site of
adhesion formation, integrins provide traction for the forward movement of cell body
and alter cytoskeletal dynamics by acting as mechanosensors. Adhesion
disassembly at both leading and trailing edges allow tail retraction and new
protrusion formation, leading to cell’s forward motion (Adopted from Ridely et al.,
2003 with permission from AAAS).
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In addition to integrins, multiple signaling molecules are involved in cell
migration. For example, talin acts as a link between integrins and the actin
cytoskeleton and regulates integrin-actin associations (Zhang et al., 2008; Cram et
al., 2003). Mice genetically null for talin are embryonic lethal due to defective
cytoskeletal organization and cell migration (Monkley et al., 2000). Vinculin is an
actin binding protein that localizes to focal adhesions. Fibroblasts that lack vinculin
expression showed increased cell migration whereas vinculin overexpressing cells
displayed decreased cell migration (Xu et al., 1998; Rodriguez Fernandez et al.,
1992). Vinculin is thought to be required to strengthen the linkage between talin and
the actin cytoskeleton (Legate et al., 2009). Actin dynamics are regulated by Rho
GTPases. RhoA, Rac, and cdc42 modulate cell contractility, lamellipodium
formation, and cell polarity, respectively (Fukata et al., 2003; Legate et al., 2009;
van Hengel et al., 2008). In addition, FAK is a signaling molecule that is activated
early in cell migration and is crucial for focal adhesion turnover that promotes
directional cell motility (Mitra et al., 2005)
Band 4.1B is a cytoskeletal adaptor protein that has been postulated to be
important for a wide range of cellular processes, including cell motility. In sarcoma
cell lines, the decreased expression of Band 4.1B enhanced cell motility and
promoted metastatic phenotypes, whereas the re-expression of Band 4.1B in these
cells reduced cell migration (Cavanna et al., 2007). However, the mechanisms by
which Band 4.1B regulates cell migration are unknown. Determining how Band 4.1B
affects these cellular events will lead to novel understanding of cell migration
signaling cascades.
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1.2. Protein 4.1 superfamily
Band 4.1B belongs to the protein 4.1 superfamily (Parra et al., 2000). All
members of this superfamily contain an N-terminal band 4.1, ezrin, radixin, and
moesin (FERM) domain (Sun et al., 2002). The protein 4.1 superfamily can be
subdivided into five groups based on the protein sequence similarity: protein 4.1
family, ERM proteins, talin-related molecules, protein tyrosine phosphatases
(PTPH), and novel band 4.1-like 4 (NBL4) proteins (Figure 2).
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Figure 2. Protein 4.1 superfamily.
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Figure 2. Protein 4.1 superfamily.
The members of the protein 4.1 superfamily are characterized by the presence of
an N-terminal FERM domain. About 50 members have been identified to date. The
members are divided into five subfamilies based on sequence homology: protein
4.1 family, ERM proteins, talin-related molecules, protein tyrosine phosphatases
(PTPH), and novel band 4.1-like 4 (NBL4) proteins. FERM, Protein 4.1-ezrinradixin-moesin domain; ABD actin-binding domain; CCR, coiled-coil region; CTD,
carboxyl terminal domain; PTP, protein tyrosine phosphatase; SABD, spectrin-actin
binding domain; U1, U2, U3, unique regions (Adopted from Sun et al., 2002 with
permission from J Cell Sci).
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These proteins not only provide links between the cell membrane and the actin
cytoskeleton, but also play roles in cell adhesion, proliferation, motility, cell cycle
regulation, and various other intracellular signaling (Diakowski et al., 2006).
The protein 4.1 family consists of Band 4.1R (erythrocyte), Band 4.1G
(general), Band 4.1B (brain), Band 4.1N (neuronal), and Band 4.1O (ovary). The
name 4.1 was given based on the band position of Band 4.1R, the first member
identified, on 2D SDS polyacrylamide gel electrophoresis (Holzwarth et al., 1976).
Erythrocyte membrane proteins were separated by SDS-PAGE and named
according to their motility on gel electrophoresis. The band with slowest mobility
was named band 1, and the fastest migrating band was named band 7. As
resolution improved, additional bands were named using decimals. Bands 1-3 and
5-7 were identified as spectrin, ankyrin, anion transport exchanger, actin, G3PD,
and stomatin, respectively. However, the name of 4th band remained Band 4.1
(Yawata, 2003).
In addition to the N-terminal FERM domain, the members of the protein 4.1
family contain an internal spectrin actin binding domain (SABD), a C-terminal
domain (CTD), and three unique domains (Sun et al., 2002) (Figure 2). The FERM
domain, SABD, and CTD are highly conserved among the various members. The
30kDa FERM domain is made of three lobes that form a clover leaf-like structure
(Han et al., 2000). The FERM domains of Band 4.1G, Band 4.1B, and Band 4.1N
share 74%, 73%, and 71% structural similarities with Band 4.1R, respectively (Sun
et al., 2002). This domain interacts with multiple integral membrane proteins, such
as glycophorin C, p55, and calmodulin (Gascard and Cohen, 1994; Marfatia et al.,
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1994; Nunomura et al., 2000). The 10kDa SABD binds spectrin and actin, as the
name suggests (Correas et al., 1986), although Band 4.1N’s SABD does not
interact with spectrin and actin (Gimm et al., 2002). By forming the spectrin-actin
complex, this domain influences membrane stability (Diakowski et al., 2006). The
22/24kDa CTD is crucial for interacting with cell surface proteins, including occludin,
zonula occludens-1, and zonula occludens-2 (Mattagajasingh et al., 2000), as well
as a translational complex subunit, eIF3-p44 (Hou et al., 2000).
Each member of the protein 4.1 family is encoded by genes located on
different chromosomes and has somewhat overlapping tissue expression patterns
(Table 1).

Table 1. Protein 4.1 family (Adopted from Sun et al., 2002 with permission from J
Cell Sci)
Protein

Chromosome

Tissue Distribution

4.1R

1p36.2-p34

Erythrocytes, brain

4.1G

6q23

Heart, brain, placenta,
lung, skeletal muscle,
kidney, pancreas, gonads

4.1N

20q11.2-q12

Brain, peripheral nerve

4.1B

18p11.3

Brain, heart, lung, kidney,
intestine, testis, adrenal
gland

4.1O

9q21-22
10

Ovary

Four of the members are expressed in the brain, although they are found in different
cell populations. For example, Band 4.1N is expressed in virtually all neurons
(Walensky et al., 1999) whereas Band 4.1R is localized in granule cells of the
cerebellum and dentate gyrus (Walensky et al., 1998). Band 4.1B is found in
purkinje cells of the cerebellum, pyramidal cells of the hippocampus, neurons of
thalamic nuclei and olfactory bulbs (Parra et al., 2000).
The ERM family is composed of ezrin, radixin, moesin, and merlin. These
proteins share approximately 75% sequence homology (Diakowski et al., 2006).
The members of the ERM family is characterized by the presence of an N-terminal
ERM association domain (N-ERMAD) and a C-terminal actin-binding domain (CERMAD) that are separated by an α-helical coiled coil region (CCR) (Sun et al.,
2002) (Figure 2). The FERM domains of ERM proteins and merlin share about 30%
structural similarities with Band 4.1R (Sun et al., 2002). These proteins have been
implicated in connecting the actin cytoskeleton to CD43, CD44, ICAM1-3, Na+/H+
exchanger-3, and cystic fibrosis transmembrane regulator (Bretscher et al., 2002).
Merlin, also known as neurofibromatosis 2 (NF2) or schwannomin, is a
schwannoma suppressor that regulates cell proliferation and motility (Shermen and
Gutmann, 2001). ERM protein activation is regulated by conformational changes
(Fehon et al., 2010). ERM proteins exist in inactive state where they maintain
closed conformation by binding of C-ERMAD to the FERM domain (Gary and
Bretscher 1995). Release of C-ERMAD from the FERM domain activates ERM
proteins and exposes binding sites in these two domains, including the F-actin
binding site in C-ERMAD (Fehon et al., 2010). Each ERM protein has a
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phosphorylation site that is important for its activation. Moesin, ezrin, and radixin are
phosphorylated on Thr558, Thr576, and Thr564, respectively (Nakamura et al.,
1995; Fievet et al., 2004). Multiple kinases have been shown to phosphorylate
these Thr residues, including Rho kinase, protein kinase Cα (PKCα), PKCθ, NF-kβinducing kinase, and lymphocyte-oriented kinase (Matsui et al., 1998; Ng et al.,
2001; Belkina et al., 2009; Simons et al., 1998). In addition, other phosphorylation
sites have been demonstrated to be involved in ERM activation. Thr235 can be
phosphorylated by cyclin-dependant kinase 5 (CDK5) (Yang and Hinds 2003).
Furthermore, Tyr145 and Tyr553 on ezrin are phosphorylated by epidermal growth
factor receptor (EGFR) (Krieg and Hunter, 1992).
Talin forms an anti-parallel rod-shaped homodimer that contains an Nterminal FERM domain, sharing 20% sequence similarity with Band 4.1R (Anthis
and Campbell, 2011) (Figure 2). The FERM domain consists of F1, F2, and F3
subdomains (Moser et al., 2009). The F3 domain is similar to phosphotyrosine
binding

(PTB)

domain,

and

binds

to

the

integrin

cytoplasmic

tails,

phosphatidylinositol 4-phosphate 5-kinase γ (PIPKI γ), and layilin (Anthis and
Campbell, 2011). The rod domain contains binding sites for vinculin and a second
integrin binding site (Critchley and Gingras, 2008). The N-terminal FERM domain is
50 kDa and the C-terminal rod is 220kDa (Calderood, 2004). Talin localizes to focal
adhesions and the membrane ruffles of migrating cells (Critchley, 2000). Talin plays
crucial roles in integrin signaling, focal adhesion formation and organization, and
cell migration (Shattil et al., 2010; Critchley, 2009; Zhang et al., 2008; Calderwood
and Ginsberg, 2003).
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The PTPH family consists of PTPH1 and PTPMEG that contain an Nterminal FERM domain and a C-terminal phosphatase domain (Gu et al., 1991)
(Figure 2). The FERM domain of the PTPH proteins has 37% sequence homology
with Band 4.1R (Sun et al., 2002).They are involved in regulating cytoskeletal
dynamics, cell cycle progression, and cell proliferation (Diakowski et al., 2006).
NBL4 also has an N-terminal FERM domain that shares 40% sequence identity with
Band 4.1R (Sun et al., 2002) (Figure 2). NBL4 functions as a regulator of cell
polarity, proliferation, and migration by being a part of the β catenin/Tcf signaling
cascade (Ishiguro et al., 2000).

1.3. Band 4.1B
Band 4.1B, a member of the protein 4.1 family, was originally discovered in
non-small cell lung carcinomas. Differentially expressed in adenocarcinoma of lung
(DAL-1), a truncated Band 4.1B gene that lacks complete U1 and CTD, and partial
U2 and SABD, was found to be absent in these tumors by differential display
reverse transcriptase polymerase chain reaction (RT-PCR) (Tran et al., 1999). The
full length protein has a molecular mass of 125-145kDa depending on alternative
splicing (Tran et al., 1999). Alternatively spliced forms of Band 4.1B are expressed
in a tissue specific manner. Band 4.1B is the most abundant member of the protein
4.1 family in the brain. In situ hybridization has shown that 4.1B mRNA is highly
concentrated in the cerebellum, hippocampus, thalamic nuclei, and olfactory bulb
(Parra et al., 2000). In addition, Band 4.1B is found in the heart, lungs, kidneys,
intestine, testes, adrenal glands, and skeletal muscle (Parra et al., 2000).
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Subcellularly, this protein is localized to the plasma membrane where cells make
contact with one another, suggesting its functions in cell-cell/cell-matrix interactions
(Parra et al., 2000).
Most of the studies on Band 4.1B have focused on its potential roles in tumor
suppression and progression. Since its original discovery (Tran et al., 1999), Band
4.1B gene expression has been shown to be down-regulated in various tumors,
including meningiomas and carcinomas of breast, kidney, colon/rectum, and
prostate. Expressing DAL-1 in the non-small cell lung carcinomas that lacked DAL1 expression resulted in suppression of tumor growth, suggesting its role as a
negative growth regulator (Tran et al., 1999). Loss of heterozygosity in the
chromosome 18p11.3 where Band 4.1B is located has been reported in 38% of
non-small cell lung carcinomas (Tran et al., 1999) and 76% of sporadic
meningiomas (Gutmann et al., 2001), further providing evidence for Band 4.1B as a
tumor suppressor. Recently, a Band 4.1B knockout mouse model was developed to
characterize the functions of Band 4.1B in tumorigenesis. Interestingly, these mice
were not prone to develop tumors (Yi et al., 2005). No differences in cell
proliferation and apoptosis were found between the Band 4.1B wild type and
knockout mice (Yi et al., 2005). However, unlike the 4.1B knockout mice, Band 4.1B
deficient transgenic adenocarcinoma of the mouse prostate (TRAMP) mice
developed tumors that displayed more aggressive and highly metastatic phenotypes
(Wong et al., 2007). These suggest that Band 4.1B is critical for tumor progression
and metastasis, rather than tumor formation. Alternatively, Band 4.1B mutations in
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combination with other mutations in oncogenes or tumor suppressors may promote
tumor formation.
Another member of the protein 4.1 superfamily, merlin, is a well established
tumor suppressor protein. Merlin has been demonstrated to negatively regulate
several cellular properties that are important for cell-cell and cell-substrate
interactions. Merlin impairs cell motility, attachment, and spreading (Gutmann et al.,
1999). It has been also suggested that merlin inhibits cell proliferation by modulating
cell adhesion (Gutmann et al, 1999). Given the homology between merlin and Band
4.1B, Band 4.1B may function similarly to merlin, regulating various intracellular
signaling pathways. Abnormal regulation of these processes in the absence of Band
4.1B may lead to tumor progression and metastasis in tumors lacking Band 4.1B.
Indeed, Band 4.1B has been shown to suppress cell proliferation in meningiomas
(Gutmann et al., 2001). In addition, metastatic sarcoma cell lines with loss of Band
4.1B expression have displayed increased motility and chemotactic responses
(Cavanna et al., 2007).
Despite the proposed roles of Band 4.1B, the mechanisms by which Band
4.1B contributes to various intracellular signaling cascades are not clear. One
approach to studying Band 4.1B’s functions is to examine the binding partners of
Band 4.1B. Each domain of Band 4.1B interacts with a different set of proteins
(Bernkopf and Williams, 2008) (Figure 3).
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Figure 3. Each conserved domain of Band 4.1B interacts with unique binding
partners.
Multiple proteins have been identified to interact with Band 4.1B. Each domain of
Band 4.1B binds to a set of molecules without overlaps with other conserved
regions. The FERM domain interacts with various transmembrane proteins. The
SABD is involved in spectrin-actin complex formation, as the name suggests. The
CTD domain appears to be important for interacting with cell surface proteins.
Recently, β8 integrin was shown to interact with the CTD of Band 4.1B via its
cytoplasmic tail (Adopted from Bernkopf and Williams, 2008 with permission from
Ashley Publications Ltd).
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McCarty and colleagues identified β8 integrin as an interacting molecule of Band
4.1B (2005a). The cytoplasmic tail of β8 integrin interacts with the CTD of Band
4.1B as demonstrated by the yeast two-hybrid study and co-immunoprecipitation
(McCarty et al., 2005a). β8 integrin is critical for cell-matrix interactions and
intracellular signaling, especially in the central nervous system (CNS). Given the
importance of integrins in multiple cellular events, studying the functional links
between Band 4.1B and integrins will enhance our understanding of Band 4.1B’s
functional roles.

1.4. Integrin family
The integrin family of major cell adhesion receptors is comprised of 18α and
8β subunits that form 24 αβ heterodimeric receptors. Evolutionary studies indicate
that both α and β integrin genes are from a common ancestral gene by gene
duplications and that these genes are highly conserved in vertebrates (Huhtala et
al., 2005). Integrin α and β subunits are consisted of an extracellular domain, a
transmembrane helix, and a cytoplasmic tail. The extracellular domain is 700-1000
residues in length (Hynes, 2002). This portion contains a ligand binding site that is
comprised of the β propeller and the plexin-semaphorin-integrin domains of α
subunit, and the βI (or βA) and the hybrid domains of β subunit (Takada et al.,
2007). The α and β cytoplasmic tails are 25-50 residues in size except for the β4
tail, which is made of 1000 amino acids (Hynes, 2002). The α cytoplasmic domain
has a conserved GFFKR motif that is critical for αβ cytoplasmic tail interactions
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(Harbuger and Calderwood, 2008). The β subunits contain an NPxY motif in their
cytoplasmic domains, which is important for integrin activation (Takada et al., 2007).
Integrins can be divided into multiple subgroups based on their ECM ligands:
1) laminin-binding integrins, including α1β1, α2β1, α3β1, α6β1, α7β1, and α6β4; 2)
collagen-binding integrins, such as α1β1, α2β1, α3β1, α10β1, and α11β1; 3)
leukocyte integrins, including αLβ2, αMβ2, αXβ2, and αDβ2; and 4) RGD binding
integrins, like α5β1, αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, and αIIbβ3 (Hynes, 2002)
(Figure 4).
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Figure 4. Integrin family.
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Figure 4. Integrin family.
The integrin family is comprised of 18α and 8β subunits that form 24 αβ
heterodimeric receptors. Integrins can be divided into multiple subgroups based on
their ECM ligands: 1) laminin-binding integrins (green); 2) collagen-binding integrins
(purple); 3) leukocyte-specific integrins (grey); and 4) RGD binding integrins
(yellow). Various integrins have been implicated in development, angiogenesis,
lymphangiogenesis, skin integrity, immune response, bone remodeling, and
hemostasis (Adopted from Hynes, 2002 with permission from Elsevier).
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In addition, integrins can be divided into I, insertion/interaction, domain containing
(α1, α2, α10, α11, αL, αM, αX, αD, and αE) and non-containing integrins (α3, α4,
α5, α6, α7, α8, α9, αV, αIIb) (Takada et al., 2007). Each integrin has specific and
non-redundant roles as shown by the studies of integrin knockout mice. The
phenotypes of these knockout mice indicate the importance of various integrins in
development (e.g. β1), angiogenesis (e.g. α1, αV, β3), lymphangiogenesis (e.g.
α9β1), skin integrity (e.g. α6β4), immune response (e.g. αL, αM, β2, β7), bone
remodeling (e.g. β3), and hemostasis (e.g. αIIb, β3, α2) (Barczyk et al., 2010;
Harburger and Calderwood, 2008; Hynes, 2002).
Upon activation, integrins mediate cell-ECM interactions. In addition to their
role in cell adhesion, they are critical for activation of various intracellular signaling
pathways. Many intracellular proteins, such as talin, vinculin, paxillin, actin binding
proteins, and other signaling molecules, interact with the cytoplasmic domains of
integrins. Through these interactions, integrins modulate diverse cellular events,
including cell proliferation, survival, polarity, and motility (Figure 5).
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Figure 5. Integrins are involved in various intracellular signaling pathways.
Upon activation, integrins mediate cell-ECM interactions, connecting the ECM to the
actin cytoskeleton in the cytoplasm. In addition to functioning as a major adhesion
receptor, integrins play critical roles in activation of various intracellular signaling
pathways. Many intracellular proteins interact with the cytoplasmic tails of integrins.
Through these interactions, integrins modulate diverse cellular events, including cell
proliferation, survival, polarity, and motility.
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1.5. Integrin activation and signaling
Integrins on cell surfaces are often present in their inactive state, and need to
be activated for further signaling. One unique feature of integrin activation is that
intracellular signals activate integrins by inducing conformation changes and
increasing their affinity to ECM molecules. Thus, this type of activation is termed
inside-out activation (Harburger and Calderwood, 2008). The β subunit cytoplasmic
tail is important for mediating inside-out activation. The cytoplasmic tails of most αV
integrin-binding β subunits, including β1, β3, β5, and β6, contain the NPxY motif
that is crucial for interactions with an intracellular integrin activator (Calderwood,
2004) (Figure 6).
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Figure 6. Talin regulates integrin inside-out activation by interacting with the β
subunit cytoplasmic domain.
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Figure 6. Talin regulates integrin inside-out activation by interacting with the
β subunit cytoplasmic domain.
Integrins need to be activated for further signaling. Intracellular signals activate
integrins by inducing conformation changes and increasing their affinity to the ECM.
Inside-out activation of integrins is mediated by talin, a FERM domain-containing
member of the protein 4.1 superfamily. Talin binds to the NPxY motif in the β
integrin cytoplasmic tails via its FERM domain to activate integrins. Unlike other β
subunits, β8 integrin lacks the NPxY motif in its cytoplasmic tail. Therefore, β8
integrin cannot be activated by talin. The activator of β8 integrin has not been
identified (Adopted from Calderwood and Ginsberg, 2003 with permission from
Macmillan Publishers Ltd: Nat Cell Biol, copyright 2003 and McCarty et al., 2005a,
copyright National Academy of Sciences, U.S.A.).
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A common integrin activator, talin, has a FERM domain that can bind to the NPxY
motif in its globular head. The FERM domain of talin is divided into F1, F2, and F3
subdomains. The F3 domain contains a PTB that binds the integrin β tails with high
affinity (Wegener et al., 2007). Binding of talin appears to be a sufficient final step
for activating integrins. In its inactive state, the rod region of talin masks the β
subunit binding site in the FERM domain (Calderwood, 2004). The β tail binding site
can be exposed when calpain cleaves the FERM domain of talin or PtdIns(4,5)P2
binds to talin, causing a conformational change (Anthis and Campbell, 2011).
Integrin activation by talin can be inhibited by phosphorylation of the NPxY motif of
β tails, binding of other proteins to β subunits, or binding of PIPKIγ-90 to talin
(Calderwood, 2004).
The interactions between the membrane proximal regions of the α and β
cytoplasmic tails maintain integrins in their inactive state. Binding of talin to integrins
results in the disruption of the β tail membrane-proximal region and the dissociation
of the α and β tails (Calderwood, 2004). This leads to subsequent conformation
changes in the extracellular regions that increase the extracellular binding activity of
the integrins. Two models have been proposed for the conformation changes in
integrin activation. In the ‘deadbolt’ model, inactive integrins are in a bent
conformation. Upon the binding of talin, the transmembrane regions engage in
piston-like movements, causing the α and β extracellular stalks to slide. The
interactions between the headpiece and the β stalk, in turn, are disrupted (Arnaout
et al., 2005). In the ‘switch blade’ model, inactive integrins are in a bent form, as
well. However, this model suggests that the separation of the cytoplasmic and
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transmembrane domains of α and β subunits results in the dislocation of an
epidermal growth factor like repeat in the β stalk, causing outward swing of the
headpiece like a switchblade (Luo et al., 2007).

1.6. Integrin signaling and Band 4.1B
Among the αV-binding β integrins, β8 integrin does not share sequence
homology with other β subunits (McCarty et al., 2005a) (Figure 6). Because the β8
cytoplasmic tail lacks the NPxY motif, αvβ8 integrin does not interact with talin. The
regulator of αvβ8 integrin activation has not been identified. A recent study has
shown the interactions between the cytoplasmic tail of β8 integrin and the CTD of
Band 4.1B (McCarty et al., 2005a). Talin and Band 4.1B share protein sequence
homology. Therefore, the binding of Band 4.1B to αvβ8 integrin suggests that Band
4.1B, like talin, may play a role in αvβ8 integrin activation, modulating integrin
adhesion and downstream cellular events. Alternatively, Band 4.1B may participate
in the αvβ8 integrin-regulated signaling as a downstream signaling molecule.
Cell adhesion, spreading, and motility are some of the cellular events that
are regulated by integrins. A crucial component that integrates signaling required
for these processes is a focal adhesion complex. Focal adhesion complexes are
made up of integrins, signaling molecules, and adaptor proteins (Campbell, 2008).
They serve as mechanical links between the ECM and the actin cytoskeleton and
provide places for intracellular molecule recruitment and sequestration (Critchley,
2000).

Recently, talin was shown to be involved in proper organization of focal

adhesions and cell spreading that are mediated by β1 integrin (Zhang et al., 2008).

27

Both Band 4.1B and β8 integrin have been shown to localize to focal adhesions
(McCarty et al., 2005a). Band 4.1B may play a role in focal adhesion formation and
cell spreading by interacting with β8 or perhaps other β integrins. The interactions of
the Band 4.1B FERM domain with β integrins have not been studied. Piao and his
colleges have recently suggested that Band 4.1B may act as a linker between
GluR1 and β1 integrin (2009). In this study, glioma cell lines overexpressing GluR1
subunit of the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid glutamate
receptor (AMPAR) had increased baseline activation of FAK. In addition,
overexpression of GluR1 was correlated with increased expression of surface β1
integrin, which is a known FAK activator. Although GluR1 did not directly interact
with β1 integrin, GluR1 was found to bind to Band 4.1B. Therefore, the authors
concluded that FAK activation seen in the GluR1 overexpressing glioma cell lines
may be due to the effects of integrins and/or Band 4.1B on FAK activity and that
GluR1 is likely to interact with β1 integrin via Band 4.1B (Piao et al., 2009). FAK is
a non-receptor protein tyrosin kinase that contains several protein interaction
domains, including the binding sites for Src, FERM proteins, integrins, and paxillin
(Hauck et al., 2002). The FAK pathway is one of the early signaling cascades that
are activated in focal adhesions (Brown et al., 2005). Multiple protein interactions
allow FAK to modulate various signal transduction pathways, such as small GTPase
and MAPK signaling that may be critical for cell movement (Hauck et al., 2002). The
FAK activity in β1 integrin-modulated cell adhesion has been shown to be regulated
by talin (Zhang et al., 2008). Band 4.1B and its interactions with integrins have not
been associated with FAK signaling. However, it would be interesting to examine
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Band 4.1B’s roles in FAK regulation, given the similarities between Band 4.1B and
talin.
Furthermore, Band 4.1B may play a role in integrin recycling, which is an
important step in cell motility (Bel et al., 2009; Caswell and Norman 2008). A recent
study has demonstrated that the Band 4.1B-binding domain is necessary for the
endocytosis of the neural cell adhesion molecule contactin-associated protein 2
(Caspr2) (Bel et al., 2009). In addition, L1-CAM, another cell adhesion molecule,
has been shown to contain a FERM-binding motif at a site that overlaps an
endocytosis motif (Bel et al., 2009). Moreover, Numb, an endocytic adaptor that
binds directly to β integrins via its FERM domain, has been shown to co-localize
with β1 integrin in clathrin-coated structures at the leading edge of migrating cells
(Caswell and Norman, 2008). Given the prior reports, investigating Band 4.1B’s
roles in integrin trafficking would be worthwhile.

1.7. Integrins, Band 4.1B, and organogenesis
Because integrins and Band 4.1B can regulate various signaling cascades
and cellular behavior, they are likely to contribute to proper organ development and
homeostasis regulation during embryogenesis. In fact, integrin-mediated adhesion
and signaling are essential for normal heart development (Thiery, 2003). Deletion of
αV and α5 integrins causes impaired cardiac development (van der Flier et al.,
2010). In addition, deletion of EIIIA and EIIIB splice variants of fibronectin, an ECM
ligand for integrins, leads to cardiovascular abnormalities and embryonic lethality
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(Astrof et al., 2007). In humans, integrins are involved in the pathogenesis of heart
disease (Wegener et al., 2007).
Normal development of the cardiovascular system is essential for survival
and growth of embryos.

The embryonic heart develops as a linear tube and

subsequently undergoes looping, trabeculation, and compartmentalization (Jones et
al., 2008). In late gastrulation, mesoderm-derived cardiac progenitor cells migrate
from the primitive streak and form the early heart tube (Buckingham et al., 2005).
During rightward looping of the primitive heart, cardiac chambers are defined and
endocardial cushions, the precursors of the mitral and tricuspid valves in
atrioventricular (AV) canal as well as the precursors of the aorticopulmonary septum
in the outflow tract (OFT), are formed (Harvey, 2002).
The formation of the OFT is contributed by multipotent migratory neural crest
cells. Neural crest cells originating from the dorsal neural folds undergo epithelialto-mesenchymal transition (Jain et al., 2010). They migrate to and invade the OFT,
contributing significant mass to the endocardial cushions (Stoller and Epstein,
2005). The migration of neural crest cells requires interactions with various ECM,
such as fibronectin, collagen, vitronectin, and laminin, which serve as migratory
scaffolds (Delannet et al., 1994). In vitro and in vivo studies have suggested that
integrins are important for neural crest cell-ECM interactions that ensure proper
migration of the cell population (Desban and Duband, 1997; Kil et al., 1996; Perris
et al., 1989; Bronner-Fraser, 1986). Furthermore, multiple members of the protein
4.1 superfamily have been implicated in neural crest cell delamination and migration
(Acloque et al., 2009). The functions of Band 4.1B in cardiac morphogenesis have
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not been examined. Given the interactions between Band 4.1B and integrins, known
regulators of neural crest, Band 4.1B may also play a role in normal heart
development.

1.8. Specific aims
Cell migration is a critical component of normal development, wound healing,
and many diseases, including cancer.

Therefore, characterizing molecular

pathways that are involved in cell migration is crucial for understanding various
physiological and pathological processes.

Band 4.1B, a cytoskeletal adaptor

protein, has been implicated in regulation of cell motility, but the molecular
mechanisms by which Band 4.1B contributes to cell migration have not been
studied. Band 4.1B, via its CTD, interacts with the integrin αvβ8. This novel finding
has led to the examination of the functional roles for Band 4.1B in integrin-mediated
adhesion and signaling that are essential for proper cell migration.
The objective of this study was to determine how Band 4.1B is involved in
integrin-modulated adhesion and signaling pathways, and ultimately in cell
migration. The central hypothesis of this project was that Band 4.1B regulates
integrin-mediated adhesion formation and subsequent signaling cascades that are
critical for cell migration. To test the central hypothesis and accomplish the objective
of this study, the following two specific aims were pursued:
1. Specific Aim I: Elucidate the roles of Band 4.1B-β8 integrin interaction in
mouse embryonic development.
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The working hypothesis for the first aim was that the absence of Band 4.1B-β8
integrin interaction impairs cell-ECM adhesion and signaling, resulting in disrupted
cardiac neural crest cell migration.
2. Specific Aim II: Determine the functional roles for Band 4.1B in β1 integrinmediated cell adhesion and signaling in vitro.
The working hypothesis for the second aim was that Band 4.1B regulates adhesion
formation and signaling through the interactions between its FERM domain and β1
integrin during initial cell spreading.
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Chapter 2. Materials and Methods
2.1. Experimental mice
Band 4.1B and β8 integrin knockout mice have been previously generated
and characterized (Yi et al., 2005; Zhu et al., 2002). To produce various single and
double gene knockout mice for the in vivo study, 4.1B-/- mice with C57BL6/129S4
background and β8+/- mice with C57BL6/129S4/CD-1 background were crossed.
β8+/-;4.1B+/- mice generated from the cross were then interbred to generate β8+/;4.1B+/+ and β8+/-;4.1B-/- mice. Wild type, β8-/-, 4.1B-/-, and β8-/-;4.1B-/- mice
were obtained by crossing β8+/-;4.1B+/+ or β8+/-;4.1B-/- mice. Embryos were
staged based on timed matings. Noon on the plug date was defined as E0.5. To
generate wild type and 4.1B-/- mice with the same genetic background, 4.1B-/- mice
with C57BL6/129S4 background were backcrossed with wild type C57BL6 mice.
4.1B+/- mice obtained from the cross were then interbred to generate wild type and
4.1B-/- littermates.
The genotypes of progeny were determined using PCR based methods
described previously (Yi et al., 2005; Zhu et al., 2002). Briefly, tail DNA was isolated
from digesting the tissue in STE containing proteinase-K (100µg/ml, USB Scientific,
Cleveland, OH) for 16 hours at 55°C and precipitating DNA in 100% ethanol. The
extracted DNA was dissolved in TE (pH 8) at 37°C by using Thermomixer R
(Eppendorf, Westbury, NY). The samples for the PCR were prepared using
MangoMix (Bioline, Tauton, MA) according to the manufacturer’s protocol. The
primer sequences used for the β8 gene amplification are as follows: 5'ATTATCTGGTTGATGTGTCAGC-3',

5'-GGAGGCATACAGTCTAAATTGT-3',
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5'-

AGAGGCCACTTGTGTAGCGCCAAG-3', and 5'-AGAGAGGAACAAATATCCTTC
CC-3'. The PCR conditions for the β8 gene amplification are as follows: 95°C for 5
minutes x1 cycle, 95°C for 45 seconds, 58°C for 30 seconds, 72°C for 1 minute x30
cycles, 72°C for 10 minutes x1 cycle, and 4°C hold. The primer sequences used for
the 4.1B gene amplification are as follows: 5'-CGCACCTGGTGCATGACC-3', 5'CGCCACCGTCTGAGCAGC-3', and 5'-GCACGTTTGGTAGCAGTTCCC-3'. The
PCR conditions for the 4.1B gene amplification are as follows: 94°C for 5 minutes x1
cycle, 94°C for 1 minute, 61°C for 1 minute, 72°C for 1 minute x30 cycles, 72°C for
10 minutes x1 cycle, and 4°C hold.

2.2. Astrocyte isolation
Wild type and 4.1B-/- primary astrocytes that express β1 integrin were
isolated from wild type and 4.1B-/- mice between postnatal days 0-3. The brains
were removed from the neonates, and the cortices were dissected out by removing
the olfactory bulbs, hippocampi, other internal structures, and meninges.

The

cortices were diced into 1mm2 cubes and digested in low glucose Dulbecco’s
modified Eagle’s medium (DMEM) (1000mg/L glucose, Sigma, St. Louis, MO)
containing collagenase type I (Worthington, Lakewood, NJ) and deoxyribonuclease
I (Sigma, St. Louis, MO) for 30 minutes at 37°C. The digested tissues were
homogenized, filtered, and plated on laminin (Sigma, St. Louis, MO) coated T-75
flasks. The growth medium was consisted of low glucose DMEM, 10% bovine calf
serum (Thermo Scientific, Rockford, IL), and 1% penicillin-streptomycin (Sigma, St.

34

Louis, MO). After one week of growth, astrocytes were prepared for immediate use
by shaking the plates at 200rpm for 16 hours at 37°C.

2.3. Immunoblotting
Yolk sacs, hearts, and primary astrocytes were lysed in 50 mM Tris, pH7.4,
150 mM NaCl, 1% NP40, 2.5 mM EDTA, and a complete mini protease inhibitor
cocktail tablet (Roche, Mannheim, Germany). The concentrations of the lysates
were determined using a BCA protein assay kit (Thermo Scientific, Rockford, IL).
Detergent-soluble lysates were resolved by SDS-PAGE and blotted with appropriate
antibodies. The anti-4.1B, anti-β8 integrin, and anti-αv integrin antibodies have been
described previously (McCarty et al., 2005a; McCarty et al., 2005b; Mobley et al.,
2009; Tchaicha et al., 2010). Rabbit anti-4.1G and rabbit anti-4.1N antibodies were
purchased from Protein Express (Chiba, Japan). Rabbit anti-actin antibody was
obtained from Sigma (St. Louis, MO). Peroxidase-conjugated goat anti-rabbit IgG
was purchased from Jackson ImmunoResearch (West Grove, PA).

2.4. Biotinylation and immunoprecipitation
Primary astrocytes growing on laminin were labeled with 0.1µg/ml of sulfoNHS-biotin (Thermo Scientific, Rockford, IL) for 30 minutes at 37°C. After washing
the cells with PBS and TBS twice each, the cells were lysed in 50 mM Tris, pH7.4,
150 mM NaCl, 1% NP40, 2.5 mM EDTA, and a complete mini protease inhibitor
cocktail tablet. The concentrations of the lysates were determined using the Thermo
BCA protein assay kit. The lysates were pre-cleared with goat anti-rabbit-agarose

35

(Sigma, St. Louis, MO), rabbit anti-goat IgG-agarose (RDI, Flanders, NJ), or goat
anti-rat IgG-agarose (Sigma, St. Louis, MO) for 1 hour at 4°C. Then various
integrins were immunoprecipitated for 16 hours at 4°C with one of the following
antibodies: rabbit anti-α1 (Millipore, Billerica, MA), rat anti-α2 (Emfret Analytics,
Eibelstadt, Germany), rabbit anti-α3 (Millipore, Billerica, MA), rat anti-α4 (Millipore,
Billerica, MA), rat anti-α5 (Emfret Analytics, Eibelstadt, Germany), rat anti-α6
(Millipore, Billerica, MA), goat anti-α8 (Millipore, Billerica, MA), rabbit anti-αv, rat
anti-β1 (Millipore, Billerica, MA). The secondary antibodies conjugated with agarose
beads were added to the lysates for 1 hour at 4°C. The beads were washed with 50
mM Tris, pH7.4, 150 mM NaCl, 1% NP40, 2.5 mM EDTA, and a complete mini
protease inhibitor cocktail tablet, and then boiled in Laemmli buffer for 5 minutes.
The samples were resolved by SDS-PAGE and subsequently transferred to
Immobilon-P membrane (Millipore, Billerica, MA). The membrane was blocked with
3% BSA and incubated with the Vectastain ABC mix (Vector Laboratories,
Burlingame, CA) in 3% BSA. The membrane was developed using ECL reagents
(Amersham, Piscataway, NJ).

2.5. Immunohistochemistry
E10.5 embryos and yolk sacs were fixed in 4% PFA-PBS for 16 hours at 4°C
and embedded in paraffin. The sections were blocked with 10% swine or horse
serum in PBS for 1 hour at room temperature followed by incubation with
appropriate primary antibodies for 16 hours at 4°C. Then, they were washed with
PBS containing 0.1% Tween-20 and PBS. Endogenous peroxidase activity was
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blocked with 0.3% hydrogen peroxide in PBS for 10 minutes at room temperature.
The sections were incubated with appropriate secondary antibodies for 30 minutes
at room temperature. After washing with PBS containing 0.1% Tween-20 and PBS,
the sections were developed using Vectastain ABC and DAB kits (Vector
Laboratories, Burlingame, CA). Hematoxylin counterstaining was used according to
the manufacturer’s protocol (Vector Laboratories, Burlingame, CA). The following
antibodies were utilized: rabbit anti-laminin (1:100, Sigma, St. Louis, MO), mouse
anti-α smooth muscle actin (1:500, Sigma, St. Louis, MO), rabbit anti-desmin
(1:200, Abcam, Cambridge, CA), biotinylated swine anti-rabbit IgG (1:250, DAKO,
Carpinteria,

CA),

and

biotinylated

horse

anti-mouse

IgG

(1:250,

Vector

Laboratories, Burlingame, CA). The sections were analyzed and imaged using a
Zeiss Axio Imager Z1 microscope.

2.6. Immunofluorescence
E10.5 embryos and yolk sacs were fresh-frozen in Tissue-Tek OCT
compound (Sakura Finetek, Torrance, CA). Cells were fixed with 4% PFA and
permeabilized with PBS containing 0.5% NP40. The samples were blocked with
10% goat serum for 1 hour at room temperature. Appropriate primary antibodies
were then added to the samples for 16 hours at 4°C. Then the samples were
incubated with secondary antibodies for 1 hour at room temperature. The samples
were analyzed and imaged using a Zeiss Axio Imager Z1 microscope. The following
antibodies were used for immunofluorescence analyses: rabbit anti-4.1B (5μg/ml),
rabbit anti-4.1G (5μg/ml), rabbit anti-4.1N (5μg/ml), rabbit anti-αv (1:250), mouse
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anti-paxillin (1:50, BD Biosciences, Sparks, MD), rat anti-β1 (1:100), mouse antimyc (1:100, Invitrogen, Carlsbad, CA), phalloidin-Texas Red (1:50, Sigma, St.
Louis, MO), Alexa Flour 488 goat anti-rabbit IgG, Alexa Flour 488 goat anti-mouse
IgG, Alexa Flour 594 goat anti-mouse IgG, Alexa Flour 488 goat anti-rat IgG, and
Alexa Flour 594 goat anti-rat IgG (Molecular Probes, Carlsbad, CA).

2.7. Whole-mount immunostaining
Embryos were fixed in methanol:DMSO (4:1) for 2 hours at 4°C. Yolk sacs
and hearts were fixed in 4% PFA-PBS for 2 hours at 4°C. They were dehydrated in
15% methanol, 50% methanol, and 100% methanol, and stored in 100% methanol
at -20°C until use. The tissues were rehydrated, incubated in 1% H 2O2 in PBS for
1hour, and blocked in PBSMT (2% skim milk powder, 0.1% Triton X-100 in PBS) for
2 hours at room temperature. They were then incubated with rat anti-CD31 (1:100,
BD Biosciences, San Jose, CA), mouse anti-neurofilament 2H3 (3μg/ml, University
of Iowa Hybridoma Bank), rabbit anti-4.1B (5μg/ml), rabbit anti-β8 integrin (1:250),
or rabbit anti-αv integrin (1:250) for 16 hours at 4°C. The samples were washed
five times in PBSMT at room temperature for 1 hour each and incubated with
peroxidase-conjugated AffiniPure goat anti-rat IgG, goat anti-mouse IgG, or goat
anti-rabbit IgG (1:500, Jackson ImmunoResearch, West Grove, PA). They were
washed five times in PBSMT at room temperature for 1 hour each and in PBT (0.2%
BSA, 0.1% Triton X-100 in PBS) for 16 hours at 4°C. The samples were developed
using DAB kit (Vector Laboratories, Burlingame, CA) and cleared in 100% glycerol.
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2.8. Adhesion assays
Glass coverslips were coated with fibronectin (Sigma, St. Louis, MO) for 16
hours at 4°C. Primary astrocytes were plated onto the coverslips and allowed to
adhere and spread for 30 minutes, 1 hour, 2 hours or 24 hours. The cells were then
fixed with 4% PFA and permeabilized with PBS containing 0.5% NP40 for further
immunohistochemical analysis.
Wild type and 4.1B-/- astrocytes were also plated onto a laminin-coated 96
well plate for 30 minutes. The cells were washed with PBS for three times to
remove any non-adherent cells. The adherent cells were then stained with crystal
violet, and absorbance at 560nm was read using EL800 ELISA reader (BioTek
Instruments, Vienna, VA).
COS7 and 293T cells were transiently transfected with myc-tagged 4.1B
FERM, full length 4.1B, and LacZ constructs (McCarty et al., 2005a) using Effectene
transfection reagents (Qiagen, Valencia, CA). 48 hours after the transfection, the
cells were plated onto fibronectin-coated coverslips and allowed to adhere and
spread for 30 minutes, 1 hour, 2 hours, or 24 hours. In parallel, the transfected cells
were treated with P5D2 mouse anti-β1 antibody (R&D system, Minneapolis, MN)
prior to being plated onto the fibronectin-coated coverslips to block β1 integrin. After
30 minutes of the antibody treatment, these cells were plated and allowed to adhere
and spread for 30 minutes, 1 hour, 2 hours, or 24 hours. The cells were then fixed
with 4% PFA and permeabilized with PBS containing 0.5% NP40 for further
immunohistochemical analysis. After staining the adherent cells with mouse antimyc antibody, myc-positive cells were imaged using a Zeiss Axio Imager Z1
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microscope. The area of cell spreading was analyzed and quantified using ImageJ
(NIH).

2.9. Statistical analysis
All data were analyzed using student’s t-test to determine statistically significant
differences. P value less than 0.05 was considered statistically significant.
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Chapter 3. Specific Aim I
3.1 Introduction
Proper development of the cardiovascular system is key for the development
and physiology of all organs and tissues. Cardiac neural crest cells play important
roles in normal morphogenesis of the heart. During embryogenesis, neural crest
cells migrate into developing heart and get incorporated into various compartments
of the cardiovascular system. Multiple ECM, including fibronectin, collagen,
vitronectin, and laminin, function as migratory scaffolds for neural crest cells
(Delannet et al., 1994). Therefore, integrin-mediated adhesion and signaling are
crucial for normal development of the heart. Integrins are cell adhesion receptors
that mediate cell-ECM interactions. By participating in neural crest cell-ECM
interactions, integrins modulate proper migration of the neural crest cells (Desban
and Duband, 1997; Kil et al., 1996; Perris et al., 1989; Bronner-Fraser, 1986).
Interestingly, members of the protein 4.1 superfamily have been also implicated in
neural crest cell delamination and migration (Acloque et al., 2009). Considering the
involvement of integrins and Band 4.1B in a wide range of signaling cascades and
cellular behavior (Wang et al., 2010; Dafou et al., 2010; Horresh et al., 2010; Ohno
et al., 2009; Kang et al., 2009; Cavanna et al., 2007; Wong et al., 2007), these
molecules are likely to be important for organogenesis, especially for cardiovascular
development.
In particular, β8 integrin has been found to interact with the CTD of Band
4.1B via its cytoplasmic domain (McCarty et al., 2005a). β8 integrin plays a crucial
role in vascular development. As evident in β8 knockout mice, β8 integrin’s main

41

function is to regulate vascular development in the CNS (Zhu et al., 2002).
However, a small percentage of β8 integrin knockout mice were shown to have
other cardiovascular phenotypes, such as poorly vascularized yolk sacs and
enlarged pericardial cavity (Zhu et al., 2002). Unlike β8 integrin knockout mice,
Band 4.1B knockout mice do not exhibit obvious cardiovascular phenotypes (Yi et
al., 2005). Studies on the roles of other protein 4.1 family members in cardiac
function have just started to emerge. Recently, 4.1R has been implicated in the
regulation of cardiac ion channels (Baines et al., 2009).
The functional roles for β8 integrin-Band 4.1B interactions in vivo have not
been explored. In this chapter, cooperative functions for β8 integrin and Band 4.1B
in embryonic development were elucidated by using molecular genetic approaches.
The working hypothesis was that the absence of β8 integrin-Band 4.1B interactions
impairs cell-ECM adhesion and signaling, which leads to disrupted cardiac
morphogenesis.

3.2. Results
3.2.1. Genetic knockouts of β8 integrin and Band 4.1B demonstrate lethal
phenotypes by E11.5.
To study functional roles of β8 integrin and Band 4.1B in embryogenesis,
various β8 integrin, Band 4.1B single and double knockout mutants were generated.
Mice lacking the Band 4.1B gene (4.1B-/-) were initially crossed with mice with a β8
integrin heterozygous null allele (β8+/-). β8+/-;4.1B+/- mice, the F1 progeny, were
born in the expected Mendelian ratios. They were viable and fertile with no obvious
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phenotypes. β8+/-;4.1B+/- mice were then interbred to generate β8+/-;4.1B-/- and
β8+/-;4.1B+/+ mice. 4.1B-/- and β8-/-;4.1B-/- mice were obtained by interbreeding
β8+/-;4.1B-/- pairs. Wild type and β8-/- mice were produced by intercrossing β8+/;4.1B+/+ pairs. Genotypes of all mice were determined by PCR-based gene
amplification methods. Band 4.1B wild type and knockout bands were 310 and 670
bp, respectively. The sizes of β8 wild type and knockout bands were 330 and 450
bp, respectively (Figure 7).
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Figure 7. The genotypes of embryos are determined by PCR-based gene
amplication methods.
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Figure 7. The genotypes of embryos are determined by PCR-based gene
amplication methods.
Genotypes of all mice were determined by PCR-based gene amplification methods
using

tail

DNA.

The

β8

primer

ATTATCTGGTTGATGTGTCAGC-3',

sequences

are

as

follows:

5'-

5'-GGAGGCATACAGTCTAAATTGT-3',

5'-

AGAGGCCACTTGTGTAGCGCCAAG-3', 5'-AGAGAGGAACAAATATCCTTCCC-3'.
The 4.1B primer sequences are as follows: 5'-CGCACCTGGTGCATGACC-3', 5'CGCCACCGTCTGAGCAGC-3',

5'-GCACGTTTGGTAGCAGTTCCC-3'.

Gene

amplication products for each mouse stain are shown here. Band 4.1B wild type
and knockout bands were 310 and 670 bp, respectively. The sizes of β8 wild type
and knockout bands were 330 and 450 bp, respectively.
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Examining neonatal mice at postnatal day 0 (P0) demonstrated that wild type
mice and 4.1B-/- were born in higher than expected Mendelian ratios (43/139 or
31% and 60/224 or 27%, respectively vs. the expected 25%) (Table 2). However,
slightly lower than expected β8-/- mice were present at P0 (28/139 or 20% vs. the
expected 25%) (Table 2). The percentage of β8-/-;4.1B-/- being born (23/244 or
10%) was strikingly lower than the expected 25% (Table 2). The smaller numbers of
β8-/- and β8-/-;4.1B-/- neonates found at P0 suggested embryonic or early postnatal
lethality in these mice. The analysis of mice at birth is summarized in Table 2.

Table 2. Genotype distribution of mice
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At P0, wild type and 4.1B-/- mice did not display any abnormal phenotypes,
including no CNS pathologies (Figure 8E, G). However, both β8-/- and β8-/-;4.1B-/mice demonstrated intracerebral hemorrhage at birth (Figure 8F, H). These findings
were similar to the previous reports of cerebral hemorrhage in β8-/- mice (Zhu et al.,
2002; Mobley et al., 2009). No differences in the severity of hemorrhage were
observed between β8-/- and β8-/-;4.1B-/- mice.
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Figure 8. β8-/- and β8-/-;4.1B-/- mice develop intracerebral hemorrhage after
E11.5.
Intracerebral hemorrhage is observed in both embryonic and adult brains of β8-/and β8-/-;4.1B-/- mice. A-D: Images of E12.5 wild type (A), β8-/- (B), 4.1B-/- (C),
and β8-/-;4.1B-/- (D) embryos showing intracerebral hemorrhage in β8-/- (B) and
β8-/-;4.1B-/- (D), but not in wild type (A) and 4.1B-/- (C) embryos. E-H. Images of
wild type (E), β8-/- (F), 4.1B-/- (G), and β8-/-;4.1B-/- (H) brains from P0 pups.
Intracerebral hemorrhage in β8-/- (F) and β8-/-;4.1B-/- (H) is indicated in white
arrow heads.

48

All mice that survived beyond P0 were followed for survival analysis. Both wild type
(n=20) and 4.1B-/- (n=20) mice lived without any obvious abnormalities during the
period that the survival analysis was performed. However, β8-/- (n=16) and β8-/;4.1B-/- mice (n=18) started to die in the third and fourth week of the postnatal
period (Figure 9).
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Figure 9. Kaplan-Meier survival analysis.
Postnatal survival of wild type, β8-/-, 4.1B-/-, and β8-/-;4.1B-/- mice was examined
using Kaplan-Meier survival analysis. Black diamond, wild type and 4.1B-/- (n=20
each); white square, β8-/- (n=16); grey triangle, β8-/-;4.1B-/- (n=18). Most β8-/- and
β8-/-;4.1B-/- mice died in the third and fourth week of their lives. None of these mice
survived beyond P40.
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Unlike wild type and 4.1B-/- mice, β8-/- and β8-/-;4.1B-/- mice demonstrated
hunched posturing, abnormal gait, and seizure activity by the third week of their
lives (Figure 10A, B). None of these mice survived beyond P40. The lethality shown
in β8-/- and β8-/-;4.1B-/- adult mice were likely due to hydrocephalus secondary to
the intracerebral hemorrhage. Postmortem dissection of their brains revealed
thinning of the cortices and enlargement of the ventricles that resulted from severe
hydrocephalus (Figure 10D, F). Although the phenotypes of β8-/- and β8-/-;4.1B-/were severe enough to cause early lethality in these mice, these two stains did not
exhibit obvious phenotypic differences in the postnatal period.
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Figure 10. Adult β8-/- and β8-/-;4.1B-/- mice develop hydrocephalus.
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Figure 10. Adult β8-/- and β8-/-;4.1B-/- mice develop hydrocephalus.
Both β8-/- and β8-/-;4.1B-/- mice develop hydrocephalus postnatally. A-B. Images of
wild type / 4.1B-/- (A) and β8-/- / β8-/-;4.1B-/- (B) mice at 3 weeks of age. β8-/- and
β8-/-;4.1B-/- mice demonstrated hunched posturing, abnormal gait, and seizure
activity by the third week of their lives (B). C-D. Images of dissected brains of wild
type / 4.1B-/- (C) and β8-/- / β8-/-;4.1B-/- (D) mice. In β8-/- and β8-/-;4.1B-/-, grossly
thin cortices and enlarged ventricles are seen postmortem (D). E-F. Images of brain
H&E sections from wild type / 4.1B-/- (E) and β8-/- / β8-/-;4.1B-/- (F) mice. Note
enlarged ventricles secondary to hydrocephalus in β8-/- and β8-/-;4.1B-/- mouse
brains (F). V, ventricle.
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It was noted that the differences of embryonic lethality between β8-/- and β8/-;4.1B-/- were significant. Only 23 of 224 pups born from β8+/-;4.1B-/- intercrosses
were β8-/-;4.1B-/- (Table 2). This indicated 60% embryonic lethality in β8-/-;4.1B-/mice. On the other hand, 28 of 139 pups obtained from β8+/-;4.1B+/+ breeding
were β8-/-. This represented less than 20% embryonic lethality in β8-/- (Table 2).
To determine the time window of embryonic lethality in β8-/-;4.1B-/- mice,
embryos from β8+/-;4.1B+/+ and β8+/-;4.1B-/- intercrosses were analyzed at
different developmental stages. At E10.5, wild type, β8-/-, 4.1B-/-, and β8-/-;4.1B-/embryos were present in expected Mendelian ratios (34/163 or 21%, 35/163 or
22%, 43/182 or 24%, 42/182 or 23%, respectively) (Table 2). Wild type, β8-/-, and
4.1B-/- embryos at E10.5 appeared healthy without obvious abnormalities (Figure
11A-C, E-G). However, of 42 β8-/-;4.1B-/- embryos, 11 showed severe growth
retardation and hypovascularity (Figure 11D, H). Of these 11 embryos, 6 had
enlarged pericardial cavity (Figure 11H). In addition, two embryos were dead with
no detectable heartbeat and widespread necrosis.
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Figure

11.

Double

knockout

embryos

develop

lethal

cardiovascular

phenotypes.
Double knockout embryos develop lethal cardiovascular phenotypes. A–H: Images
of E10.5 wild type, β8−/−, 4.1B−/−, and β8−/−; 4.1B−/− embryos within yolk sacs
(A–D) or removed from yolk sacs (E–H). Note the normal blood vessel patterning in
the wild type (A, E) and single knockout embryos and yolk sacs (B, C, F, G). In
contrast, most double knockouts are hypovascular (arrows in D) with embryos
displaying pericardial edema (arrows in H).
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By E11.5, the viability of β8-/-;4.1B-/- embryos was significantly decreased.
Only 6 of the 78 analyzed embryos were β8-/-;4.1B-/- (8% vs. the expected 25%)
(Table 2). This represents 68% fewer than expected β8-/-;4.1B-/- embryos. The 8%
viability at E11.5 is nearly identical to the 10% viability of β8-/-;4.1B-/- neonates at
P0. This suggests that nearly all death of β8-/-;4.1B-/- occurs between E10.5 and
E11.5. The remaining 32% of β8-/-;4.1B-/- were viable. However, they exhibited
intracerebral hemorrhage that was similar to that of β8-/- mice (Figure 8B, D).

3.2.2. Cardiovascular abnormalities contribute to the lethal phenotype of β8-/;4.1B-/- embryos
The most noticeable feature of β8-/-;4.1B-/- embryos at E10.5 was their
hypovascularity (Figure 11D). Therefore, sagittal sections of E10.5 embryos were
stained with H&E or an anti-laminin antibody to further examine the vasculature.
Normal vascular morphologies were observed in the neural tubes of wild type
(Figure 12A, E) and 4.1B-/- embryos (Figure 12C, G). However, β8-/- embryos
displayed distended blood vessels in the neural tube (Figure 12B, F). Prior studies
also showed that the absence of β8 integrin impairs vascular development in the
CNS (McCarty et al., 2005b, Proctor et al., 2005). β8-/-;4.1B-/- embryos also
demonstrated defective blood vessel formation in the neural tube (Figure 12D, H).
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Figure 12. CNS vascular pathologies are seen in β8-/- and β8-/-;4.1B-/embryos.
CNS vascular pathologies in β8 integrin single knockout and double knockout
embryos. A–D: Sagittal sections from E10.5 wild type (A), β8−/− (B), 4.1B−/− (C),
and β8−/−;4.1B−/− mutants (D) were stained with H&E. Shown are 200× images
taken from neural tubes. Note the abnormal vascular patterning in the β8−/− (B) and
β8−/−;4.1B−/− neural tubes (D). E–H: Sagittal sections through wild type (E), β8−/−
(F), 4.1B−/− (G), and β8−/−;4.1B−/− mutants (H) were immunolabeled with an antilaminin antibody to identify blood vessels (white arrows). Note the abnormal neural
tube blood vessel patterning in the β8−/− and β8−/−;4.1B−/− embryos (arrows in F,
H).
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Upon

further

examination

of

β8-/-;4.1B-/-

vasculature

using

whole-mount

immunostaining with an anti-CD31 antibody, β8-/-;4.1B-/- embryos were shown to
have a less elaborate vascular network with minimal sprouting and branching
(Figure 13D). These findings are consistent with the grossly hypovascular
appearance of β8-/-;4.1B-/- embryos (Figure 11H). In comparison, wild type, β8-/-,
and 4.1B-/- embryos demonstrated an intricate network of blood vessels
accompanied with normal vascular sprouting and branching (Figure 13A-C).
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Figure 13. β8-/-;4.1B-/- mice lack an elaborate vascular network.
β8-/-;4.1B-/- embryos exhibited abnormal vascular patterning in the CNS.

A-D.

Images of anti-CD31 whole-mount stained embryo head. Note a less elaborate
vascular network with minimal branching in β8-/-;4.1B-/- (D), compared to wild type
(A), β8−/− (B), and 4.1B−/− (C).
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Hypovascular yolk sacs observed in β8-/-;4.1B-/- embryos (Figure 11D) led
to the study of the yolk sac vasculature. In order for a better examination of yolk sac
blood vessels, E10.5 wild type, β8-/-, 4.1B-/-, and β8-/-;4.1B-/- yolk sacs were
stained with H&E and an anti-CD31 antibody. Elaborate vascular networks with
adequate vessel branching were seen in wild type (Figure 14A top), β8-/- (Figure
14B top), and 4.1B-/- (Figure 14C top) yolk sacs. Furthermore, H&E-stained yolk
sacs from wild type, β8-/-, and 4.1B-/- embryos showed closely juxtaposed
endodermal and mesodermal layers of blood vessels containing nucleated red
blood cells (Figure 14A-C, bottom). On the other hand, yolk sacs from β8-/-;4.1B-/embryos displayed abnormal vascular morphologies with reduced vessel sprouting
(Figure 14D top). H&E stained β8-/-;4.1B-/- yolk sacs revealed compressed
endodermal and mesodermal layers with smaller vessel lumens and fewer
erythrocytes (Figure 14D, bottom). These findings are consistent with the grossly
hypovascular appearance of β8-/-;4.1B-/- yolk sacs.
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Figure 14. Yolk sac vascular pathologies in β8-/-;4.1B-/- embryos.
Yolk sac vascular pathologies in double knockout embryos. A–D: Yolk sacs from
E10.5 wild type (A), β8−/− (B), 4.1B−/− (C), and β8−/−; 4.1B−/− compound mutants
(D) were immunostained with an anti-CD31 antibody to reveal blood vessels. Note
the abnormal vascular patterning in the yolk sacs of double knockouts (D).
Representative H&E-stained microscopic images (400×) of yolk sacs from E10.5
wild type, β8−/−, 4.1B−/−, and β8−/−;4.1B−/− E10.5 embryos are shown in the
bottom panels (A–D). e, endoderm; m, mesoderm; bv, blood vessel.
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The abnormal findings in yolk sac vasculature suggested possible functional
importance of β8 integrin and Band 4.1B in yolk sacs. To examine the protein
expression of β8 integrin and Band 4.1B in yolk sacs, detergent-soluble E10.5 wild
type yolk sac lysates were used for immunoblotting. Interestingly, no detectable β8
integrin expression was present in yolk sacs (Figure 15D). However, αV integrin,
the sole α subunit partner of β8 integrin, was expressed in yolk sacs. In addition,
high Band 4.1B expression was detected in yolk sacs (Figure 15D). The
immunohistochemical examination revealed that Band 4.1B localized to cell-cell
contact in the endodermal layer (Figure 15C) whereas αV integrin was found in the
cell membrane of both endodermal and mesodermal layers (Figure 15B).
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Figure 15. The expression of Band 4.1B and αvβ8 integrin in yolk sacs.
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Figure 15. The expression of Band 4.1B and αvβ8 integrin in yolk sacs.
A-C: Yolk sacs from E10.5 wild type embryos were immunostained with control IgG
(A), an anti-αv (B), or an anti-4.1B (C) antibody. Note αV integrin is expressed in
both the endodermal and mesodermal layers (B) whereas Band 4.1B localizes to
the endodermal layer only. D: Detergent-soluble lysates prepared from E10.5 yolk
sacs were immunoblotted with an anti-αv, an anti-β8, or anti-4.1B rabbit polyclonal
antibody, revealing lack of detectable β8 integrin protein expression in yolk sacs.
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Lack of β8 integrin in yolk sacs ruled out cooperative functions of β8 integrin and
Band 4.1B in yolk sacs. The yolk sac phenotypes observed in β8-/-;4.1B-/- were
likely to be secondary to systemic cardiovascular abnormalities. Thus, the
expression of β8 integrin and Band 4.1B was analyzed in the heart using
immunoblot analysis of detergent-soluble E10.5 wild type heart lysates. Unlike yolk
sacs, β8 protein expression was detected in the heart (Figure 16I). αV integrin and
Band 4.1B were also present in the heart (Figure 16I). To determine protein
localization in different cardiac compartments, whole-mount immunohistochemical
analysis of the heart was performed. The hearts dissected from E10.5 wild type
embryos were immunostained with anti-αV integrin and anti-4.1B antibodies.
Various cardiac chambers expressed both αV integrin and Band 4.1B, supporting
the findings of immunoblot analysis. Band 4.1B and αV integrin were mostly
expressed in the ventricles and OFT, although less intense expression of these
proteins was present in the atria (Figure I6B-H). These findings indicate that the
extraembryonic vascular pathologies found in β8-/-;4.1B-/- are most likely due to
other cardiovascular defects.
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Figure 16. The expression of Band 4.1B and αvβ8 integrin in the embryonic heart.
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Figure 16. The expression of Band 4.1B and αvβ8 integrin in the embryonic
heart.
A, E: Schematic diagrams of anterior (A) and posterior (E) views of the E10.5
embryonic mouse heart. B-D, F-H: E10.5 mouse hearts were whole-mount
immunostained with control IgG (B, F), an anti-αv (C, G), or an anti-4.1B (D, H)
antibody. Anterior (B-D) and posterior (F-H) views of the immunostained hearts
revealed co-expression of αV integrin and Band 4.1B proteins. I: Detergent-soluble
protein lysates prepared from microdissected E10.5 hearts were immunoblotted
with anti-αv, anti-β8, and anti-4.1B antibodies revealing expression of all three
proteins. RA, right atrium; RV, right ventricle; LA, left atrium; LV, left ventricle; OFT,
outflow tract; IFT, inflow tract; AVC, atrioventricular canal.
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3.2.3. β8-/-;4.1B-/- embryos display abnormal morphogenesis of the outflow
tract and myocardium of the heart.
The morphologies of the E10.5 wild type, β8-/-, 4.1B-/-, and β8-/-;4.1B-/hearts were carefully examined by immunostaining histological sections with H&E.
The heart of β8-/-;4.1B-/- was significantly smaller than the wild type, β8-/-, and
4.1B-/- hearts. This was expected given the growth retardation observed in E10.5
β8-/-;4.1B-/- embryos. Structurally, severe hypotrophy of endocardial cushions in
the AV junction and the OFT was seen in the β8-/-;4.1B-/- heart (Figure 17D),
compared to the normal appearing wild type, β8-/-, and 4.1B-/- hearts (Figure 17AC). Furthermore, thinning of the myocardium and the OFT vessel wall was observed
in the β8-/-;4.1B-/- heart (Figure 17D).
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Figure 17. Defective heart morphogenesis in β8-/-;4.1B-/- embryos.
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Figure 17. Defective heart morphogenesis in β8-/-;4.1B-/- embryos.
A–D: Sagittal sections cut at the level of the aorticopulmonary septum from wild
type (A), β8−/− (B), 4.1B−/− (C), and β8−/−;4.1B−/− (D) embryos (E10.5) stained
with H&E (100× magnification). Note the size-reduced heart and conotruncal
cushion hypotrophy in the β8−/−;4.1B−/− mutant embryo (D). E–H: Sagittal sections
from wild type (E), β8−/− (F), 4.1B−/− (G), and β8−/−;4.1B−/− (H) embryos (E10.5)
were immunostained with an anti-αSMA antibody. Note the decreased expression
of αSMA at the level of the OFT in the double knockout embryo, shown at 100×
magnification. I–L: Higher magnification images of boxed areas in E–H (200×)
showing the OFT from wild type (I), β8−/− (J), 4.1B−/− (K), and β8−/−;4.1B−/− (L)
embryos (E10.5), highlighting reduced expression of αSMA in double knockout
embryos. A, atrium; V, ventricle; ec, endocardial cushion; M, myocardium; Tr,
trabeculae; OFT, outflow tract.
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Neural crest cells that express smooth muscle markers, in part, contribute to
the formation of endocardial cushions of the AV junction and OFT. Therefore, the
wild type, β8-/-, 4.1B-/-, and β8-/-;4.1B-/- hearts were stained with an anti-α smooth
muscle actin (SMA) for further analysis. In comparison to the wild type (Figure 17E,
I), β8-/- (Figure 17F, J) and 4.1B-/- (Figure 17G, K) embryonic hearts, the β8-/;4.1B-/- heart showed decreased αSMA expression in the OFT mesenchyme and
myocardium (Figure 17H, L). In addition, the expression of desmin, another smooth
muscle marker, was reduced in the OFT and myocardium of β8-/-;4.1B-/- embryos
(Figure 18D), compared to normal desmin expression in wild type (Figure 18A), β8/- (Figure 18B), and 4.1B-/- (Figure 18C) embryos.

71

Figure 18. Reduced expression of desmin in β8-/-;4.1B-/- embryos.
A–D: Sagittal sections cut at the level of the aorticopulmonary septum from wild
type (A), β8−/− (B), 4.1B−/− (C), and β8−/−;4.1B−/− (D) embryos (E10.5)
immunostained with an anti-Desmin antibody. Shown at 200×. Note the reduced
expression of desmin protein in double knockout embryos (D).
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Given the abnormal morphologies of the β8-/-;4.1B-/- OFT and myocardium,
the protein expression patterns of αV integrin and Band 4.1B in these structures
were examined. Fresh-frozen E10.5 wild type embryo was immunofluorescently
labeled with an anti-αV integrin or an anti-4.1B antibody. Both αV integrin and Band
4.1B were detected in endocardial cushions of the AV junction and OFT as well as
in the myocardium (Figure 19). Subcellularly, these proteins were present in cell-cell
contact (Figure 19).
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Figure 19. αV integrin and Band 4.1B proteins are co-expressed in the embryonic
heart.
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Figure 19. αV integrin and Band 4.1B proteins are co-expressed in the
embryonic heart.
A, D, G: H&E stained E10.5 wild type heart shown at 100x. Boxed areas correspond
with immunofluorescently labeled areas of the heart shown adjacent to the H&E
sections. B-C, E-F, H-I: Frozen sagittal sections from E10.5 wild type embryos were
immunofluorescently labeled with an anti-4.1B (B, E, H) or an anti-αv (C, F, I)
antibody. Shown at 200x. Note that αv integrin and 4.1B protein are co-expressed in
the myocardium and mesenchyme of the AV canal and OFT. A, aorta; V, ventricle;
OFT, outflow tract; M, myocardium; Tr, trabeculae; ec, endocardial cushion.
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β8 integrin exclusively pairs with αV integrin (Moyle et al., 1991). Since β8 integrin
expression in the heart was confirmed by immunoblotting, it is safe to conclude that
αV integrin localization patterns seen in the immunofluorescently labeled heart
reflect β8 integrin expression patterns.

3.2.4. Neural crest cell migration is impaired in β8-/-;4.1B-/- embryos.
The migration of cardiac neural crest cells is critical for the morphogenesis of
the heart (Snarr et al., 2008). Given the contribution of neural crest cells in OFT
formation and the defective OFT morphologies observed in the β8-/-;4.1B-/-, neural
crest patterning in embryos was examined. E10.5 wild type (n=6), β8-/- (n=4), 4.1B/- (n=7), and β8-/-;4.1B-/- (n=5) embryos were stained with an anti-neurofilament
antibody 2H3 using whole-mount immunostaining methods. Wild type, β8-/-, and
4.1B-/- embryos displayed an elaborate network of neurofilament positive
projections (Figure 20A-C). However, 3 out of 5 β8-/-;4.1B-/- embryos that were
examined exhibited a defective neurofilament network throughout the body (Figure
20D).
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Figure 20. Abnormal patterns of neurofilament expression in β8-/-;4.1B-/embryos.
A–D: Wild type (A), β8−/− (B), 4.1B−/− (C), or β8−/−; 4.1B−/− (D) embryos (E10.5)
were whole-mount immunostained with an anti-neurofilament monoclonal antibody,
2H3. The axonal projections from the trigeminal ganglion are prominent in wild type
and single knockouts (white arrows in A–C). In contrast, the lack of distal
projections from the trigeminal nerves (upper black arrowheads in D) and the
shortened distal projections into the pharyngeal arches (bottom arrowhead, D) were
noted in double knockout mice.
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In β8-/-;4.1B-/- embryos, the size of the trigeminal ganglion of cranial nerve V was
reduced (Figure 20D). In addition, the ophthalmic, maxillary, and mandibular
branches of cranial nerve V showed shortened projections. Furthermore,
neurofilament-positive projections of cranial nerves into the pharyngeal arches were
lacking in β8-/-;4.1B-/- embryos (Figure 20D). Abnormal neurofilament patterning
was also observed in the trunks of β8-/-;4.1B-/- embryos (Figure 21 D).
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Figure 21. Neurofilament expression patterns are abnormal in β8-/-;4.1B-/- trunks.
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Figure 21. Neurofilament expression patterns are abnormal in β8-/-;4.1B-/trunks.
A–D: Images of trunk regions from E10.5 wild type (A), β8−/− (B), 4.1B−/− (C), and
β8−/−;4.1B−/− (D) embryos. Note the normal neural crest patterning in wild type
and single knockouts (white arrows in A–C). In contrast, note the abnormal
patterning of neurofilament-expressing cells in the double knockout embryo (white
arrows in D).
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3.3. Discussion
Various in vitro studies have shown the direct binding of β8 integrin and
Band 4.1B (McCarty et al., 2005a). However, cooperative functions for these two
proteins have not been determined. This study was the first to demonstrate in vivo
functional links between β8 integrin and Band 4.1B using gene knockout strategies.
The data presented here show that ablation of β8 integrin and Band 4.1B results in
embryonic lethality by E11.5 and that this is likely secondary to abnormal cardiac
morphogenesis. β8 integrin’s roles in CNS vascular development have been well
documented in multiple previous reports (Zhu et al., 2002; Mobley et al., 2009;
Tchaicha et al., 2010). However, this study established that β8 integrin regulates
non-CNS vascular development by cooperatively signaling with Band 4.1B.
Interestingly, the lethal cardiovascular phenotypes of β8-/-;4.1B-/- embryos
were partially penetrant. The lethality seen in these mice may be affected by their
background strain variation. In fact, strain-dependent phenotypes of β8-/- mice have
been documented. In the study done by Zhu and colleagues, over 50% of β8-/mice with C57BL6/129S4 background died at mid-gestation, owing to placenta
defects

(2002).

However,

another

study

reported

that

β8-/-

mice

with

C57BL6/129S4/CD1 background were born alive without displaying embryonic
lethality (Mobley et al., 2009). These differences indicate that genetic modifiers of
the lethal phenotypes might be present in a strain-specific manner. β8-/- and β8-/;4.1B-/- mice used in this study were generated by crossing parental strains with
C57BL6/129S4 and C57BL6/129S4/CD1 backgrounds. Indeed, these mice did not
exhibit placental abnormalities.
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Grossly,

the

most

striking

feature

of

β8-/-;4.1B-/-

at

E10.5

was

hypovascularity of the yolk sac and embryo proper. The yolk sac is the first site of
erythrocyte generation (McGrath et al., 2003). The connection of the yolk sac and
systemic vasculature establishes functional circulation in embryos (McGrath et al.,
2003). Therefore, functional abnormalities in the yolk sac can be lethal to embryos.
Indeed, abnormal vascular morphologies with reduced vessel sprouting were
observed in β8-/-;4.1B-/- yolk sacs. These yolk sacs also exhibited compressed
endodermal and mesodermal layers with smaller vessel lumens and fewer
erythrocytes. These findings were consistent with the grossly hypovascular
appearance of β8-/-;4.1B-/- yolk sacs. However, no detectable expression of β8
integrin was measured in β8-/-;4.1B-/- yolk sacs, indicating that cooperative
signaling of β8 integrin and Band 4.1B does not occur in yolk sacs. Therefore, the
abnormalities displayed in β8-/-;4.1B-/- yolk sacs are not likely the primary cause of
embryonic death. They are rather likely to be the secondary effects of impairments
elsewhere.
Defective systemic circulation can lead to vascular abnormalities in
extraembryonic tissues and multiple organ systems. In addition to the abnormal
findings in β8-/-;4.1B-/- yolk sacs, blood vessels in the neural tube of β8-/-;4.1B-/embryos were found to be impaired. The neural tube contained distended blood
vessels and showed a less elaborate vascular network with minimal branching.
These vascular phenotypes were consistent with the grossly hypovascular
appearance of β8-/-;4.1B-/- embryos. Multiple defects in the vasculatures of
extraembryonic and embryonic tissues indicated impaired cardiac structures and/or
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functions. Cardiovascular defects causing early embryonic lethality include
abnormal heart specification and/or poor cardiac function (Conway et al., 2003). In
fact, pericardial edema was notable in multiple β8-/-;4.1B-/- embryos upon careful
examination. Pericardial edema is a sign of poorly functioning heart (Conway et al.,
2003). Multiple knockout mice with pericardial edema, such as PDGFα receptor
knockouts, have been shown to have OFT and AV septal defects (Soriano, 1997).
Similarly, β8-/-;4.1B-/- embryos displayed hypotrophic endocardial cushions of the
AV junction and OFT with diminished expression of neural crest cell makers.
The generation and incorporation of mesenchymal cells, including neural
crest cells, are crucial for proper heart development (Snarr et al., 2008). AV and
OFT cushions are two main cardiac mesenchymal structures. AV cushions
contribute to the formation of AV valves and septa whereas OFT cushions generate
aorticopulmonary septum (Snarr et al., 2008). Cardiac neural crest cells are
especially important for the development of the OFT. Neural crest cells are located
between the otic placode and the third/fourth somite (Stoller and Epstein, 2005).
These cells migrate through the third, fourth, and sixth pharyngeal arches to the
heart (Snarr et al., 2008). Ablating neural crest cells resulted in impairments of the
OFT and aortic arch (Kirby et al., 1983). Given that similar OFT abnormalities in
other mouse models are caused by cardiac neural crest migration defects (Conway
et al., 2003), the abnormal cardiac morphogenesis seen in β8-/-;4.1B-/- embryos
might also be due to impaired neural crest migration. Most E10.5 β8-/-;4.1B-/embryos, indeed, demonstrated a defective network of neurofilament throughout the
body with shortened projections of the ophthalmic, maxillary, and mandibular
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branches of cranial nerve V and absent projections of cranial nerves to the
pharyngeal arches. Therefore, β8 integrin and Band 4.1B are likely to cooperatively
function to support neural crest cell migration to the OFT and possibly other regions
of the developing heart. In fact, multiple αV-binding β integrins have been implicated
in neural crest cell adhesion and migration in vitro (Delannet et al., 1994).
Bone morphogenetic proteins (BMP) and transforming growth factor beta
(TGFβ) have been demonstrated to be important for cardiac morphogenesis
(Monzen et al., 2002; Sanford et al., 1997). The disruption of BMP and TGFβ
signaling has been shown to induce impairments of cardiac neural crest-mediated
OFT formation. β8 integrin is involved in signaling of the TGFβ family members.
Therefore, it is possible that β8 integrin and Band 4.1B may cooperatively regulate
TGFβ signaling in neural crest cells. In addition to cardiac morphogenesis, neural
crest cells participate in palate development (Smith and Tallquist, 2010).
Interestingly, mice genetically null for αV, β8, or TGFβ3 all have impaired palate
formation (Bader et al., 1998; Zhu et al., 2002; Proetzel et al., 1995). Furthermore,
cleft palate and structurally abnormal OFT are seen with selective ablation of TGFβ
receptors or Smads in neural crest cells (Wurdak et al., 2005; Nie et al., 2008).
Collectively, it is highly possible that β8 integrin and Band 4.1B exert their effects on
neural crest cells by modulating TGFβ signaling pathways.
Alternatively, β8 integrin and Band 4.1B may work together to promote
cardiac neural crest cell growth and survival after cardiac neural crest cells get
incorporated into the OFT. Thinning of the OFT and cardiac chamber walls were
observed in β8-/-;4.1B-/- embryos. However, increased apoptosis or decreased cell
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proliferation were not seen in the β8-/-;4.1B-/- heart. Normal OFT development also
involves mesoderm-derived endocardial cells (Acloque et al., 2009). Thus, β8
integrin and Band 4.1B may play roles in regulating other cell types as well. Neural
crest cells undergo endothelial-to-mesenchymal transformation (EMT) before
beginning their migration to the heart (Stoller and Epstein, 2005). Therefore, the
involvement of β8 integrin and Band 4.1B in EMT is also possible.
The cardiovascular phenotypes seen in β8-/-;4.1B-/- embryos occur in the
absence of both β8 integrin and Band 4.1B. This suggests cooperative functions of
these two proteins. Another possibility, however, is that β8 integrin and Band 4.1B
may act in parallel and/or redundant signaling pathways. In case Band 4.1B
regulates downstream signaling pathways of β8 integrin and other cell surface
receptors, Band 4.1B’s functions would be unaltered in the absence of β8 integrin.
Lethal cardiovascular phenotypes have been demonstrated in mice that are
genetically null for αV and α5 integrins (van der Flier et al., 2010). This opens up the
possibility that Band 4.1B may function as an intracellular signaling link between
multiple integrins. The FERM domain of Band 4.1B may interact with β subunits and
other cell surface receptors while the CTD binds to β8 integrin (McCarty et al.,
2005a), enabling Band 4.1B to incorporate multiple signaling pathways.
Defective OFT is a common feature of congenital heart disease, the most
frequently occurring birth defect in humans. One example of congenital heart
disease is DiGeorge syndrome. Individuals with DiGeorge syndrome have
abnormalities in many structures derived from neural crest cells, including the OFT
and aortic arch (Stoller and Epstein, 2005). β8 integrin and Band 4.1B have not

85

been studied in human heart diseases. Given the cardiac defects seen in β8-/;4.1B-/- embryos, it would be interesting to see if β8 integrin and Band 4.1B play
roles in human congenital heart disease.
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Chapter 4. Specific Aim II
4.1. Introduction
The members of the protein 4.1 superfamily function as links between the
cell membrane and the actin cytoskeleton, but also play important roles in cell
adhesion, proliferation, and motility, and other intracellular signaling pathways
(Diakowski et al., 2006). Band 4.1B, a cytoskeletal adaptor protein, has been
implicated in regulation of various cellular events, but the molecular mechanisms by
which Band 4.1B contributes to these signaling cascades have not been
determined. Efforts have been made to identify binding partners of Band 4.1B to
better understand the functional roles for Band 4.1B. The discovery of the
interaction between β8 integrin and Band 4.1B (McCarty et al., 2005a) has led to
the examination of Band 4.1B’s roles in integrin-mediated adhesion and signaling
that are essential for a variety of cellular events.
Cell adhesion, spreading, and motility are some events regulated by
integrins. Integrins are also important for coordinating cell-ECM interactions,
adhesion formation, and cytoskeleton organization during cell movement (Barczyk
et al., 2010; Legate et al., 2009; Harburger and Calerwood, 2009). A focal adhesion
complex is a crucial component that integrates signaling required for cell motility.
Several molecules that belong to the protein 4.1 superfamily have been shown to
modulate focal adhesion formation and cell migration that are mediated by integrins.
In particular, talin, a protein that shares sequence homology with Band 4.1B, has
been demonstrated to regulate β1 integrin-mediated focal adhesion assembly and
cell spreading (Zhang et al., 2008). Given the structural similarity between talin and
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Band 4.1B, Band 4.1B may also play a role in focal adhesion formation and cell
spreading by interacting with β8 or perhaps other β integrins. Previously, the
association between Band 4.1B and β1 integrin has been postulated (Piao et al.,
2009), but the interaction between these two proteins has never been examined.
Given the importance of the FERM domain in integrin binding and activation, Band
4.1B may help proper localization of β1 integrin to newly forming adhesions through
physical interactions and/or influence intracellular signaling of β1 integrin at the
adhesion sites.
In this chapter, the in vitro functional roles for Band 4.1B in integrin-mediated
cell adhesion and signaling were investigated. The working hypothesis was that
Band 4.1B regulates β1 integrin-mediated cell-ECM interaction and signaling via its
FERM domain during initial cell spreading.

4.2. Results
4.2.1. Lack of Band 4.1B expression does not affect integrin expression in
astrocytes.
To characterize the expression of Band 4.1B and other members of the
protein 4.1 family in astrocytes, detergent-soluble wild type and 4.1B-/- astrocyte
lysates were immunoblotted with anti-4.1B, anti-4.1G, and anti-4.1N antibodies. As
expected, Band 4.1B is highly expressed in wild type, but not in 4.1B-/- astrocytes
(Figure 22). The size of Band 4.1B was 145 kDa, which was similar to previously
reported molecular weight (Sun et al., 2002). Bands 4.1G and 4.1N were strongly
expressed in both wild type and 4.1B-/- astrocytes (Figure 22).
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Figure 22. Protein 4.1 expression in astrocytes.
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Figure 22. Protein 4.1 expression in astrocytes.
Detergent-soluble wild type and 4.1B-/- astrocytes were immunoblotted with anti4.1B, anti-4.1G, and anti-4.1N antibodies. As expected, 145 kDa Band 4.1B was
highly expressed in wild type, but not in 4.1B-/- astrocytes. Bands 4.1G and 4.1N
were expressed in both wild type and 4.1B-/- astrocytes. The sizes of 4.1G and
4.1N were 150 kDa and 100 kDa, respectively. The levels of 4.1G and 4.1N
expression were not different between wild type and 4.1B-/- astrocytes.
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The sizes of Bands 4.1G and 4.1N were 150 kDa and 100 kDa, respectively. No
significant differences in the expression of these proteins were observed between
wild type and 4.1B-/- astrocytes.
Next, integrin expression in wild type and 4.1B-/- astrocytes was examined.
Astrocytes were labeled with sulfo-NHS-biotin and immunoprecipitated with various
integrin antibodies, including anti-α1, anti-α2, anti-α3, anti-α4, anti-α5, anti-α6, αntiα8, anti-αV, and anti-β1 antibodies, to detect integrins that are expressed on the cell
surface. Both wild type and 4.1B-/- astrocytes showed similar integrin expression
profiles (Figure 23). Because sulfo-NHS-biotin labeled αβ heterodimeric pairs and
these associations are maintained through the experimental manipulations,
immunoprecipitation of α subunits also revealed their β binding partners, and vice
versa. In other words, immunoprecipitation of α2, α3, α5, α6 and αV demonstrated
pairing with the predicted β subunits (Figure 23). Since β1 integrin pairs with
multiple α subunits (Figure 4), immunoprecipitation of β1 also pulled-down α1, α2,
α3, α5, α6, and αV integrins (Figure 23). The presence of Band 4.1B in astrocytes
did not affect cell surface integrin expression, i.e., the profiles of integrin expression
did not differ between wild type and 4.1B-/- astrocytes.
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Figure 23. Integrin expression in astrocytes.
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Figure 23. Integrin expression in primary mouse astrocytes.
The

astrocytes

were

cell

surface-labeled

with

sulfo-NHS-biotin

and

immunoprecipitated with various integrin antibodies. Both wild type and 4.1B-/astrocytes showed similar integrin expression profiles. Because sulfo-NHS-biotin
labeled αβ heterodimeric pairs, immunoprecipitation of α subunits also revealed
their β binding partners, and vice versa. Pull-down of α2, α3, α5, α6 and αV showed
α2β1, α3β1, α5β1, α6β1, αVβ1, and αVβ8 integrin heterodimers, respectively. Since
β1 integrin pairs with multiple α subunits, immunoprecipitation of β1 also pulleddown α1, α2, α3, α5, α6, and αV integrins. The absence of Band 4.1B in astrocytes
did not affect cell surface integrin expression.
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4.2.2.

Band

4.1B

shows

time-dependent

changes

in

its

subcellular

localization.
In many cell types, Band 4.1B has been shown to localize to the plasma
membrane where cell-cell contacts are formed (Parra et al., 2000). However, Band
4.1B’s expression patterns in astrocytes had not been determined. Therefore,
subcellular localization of Band 4.1B and other protein 4.1 was explored in
astrocytes. Wild type and 4.1B-/- astrocytes were allowed to adhere to fibronectin,
an ECM molecule, for 30 minutes. These adherent cells were then immunostained
with anti-4.1B, anti-4.1G, and anti-4.1N antibodies. Immunofluorescent analysis of
protein 4.1’s revealed that Bands 4.1B and 4.1G localized to adhesions during early
spreading. Bands 4.1B and 4.1G’s localization to adhesions were confirmed by colocalization of these proteins with paxillin, a focal adhesion marker (Figure 24A-D).
Unlike Bands 4.1B and 4.1G, Band 4.1N did not localize to adhesions, as apparent
in co-labeling analysis with paxillin (Figure 24E, F). However, Band 4.1N was
concentrated in the nucleus as it co-localized with DAPI which binds to DNA. In the
absence of Band 4.1B, astrocytes were still able to form adhesions, as
demonstrated with paxillin-positive contacts in 4.1B-/- astrocytes (Figure 24B). No
differences in localization patterns of Bands 4.1G and 4.1N were demonstrated
between wild type (Figure 24C, E) and 4.1B-/- (Figure 24D, F) astrocytes.
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Figure 24. Protein 4.1B and 4.1G, but not 4.1N, localize to cell-ECM contact sites.
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Figure 24. Protein 4.1B and 4.1G, but not 4.1N, localize to cell-ECM contact
sites.
A-F: Wild type and 4.1B-/- astrocytes were allowed to adhere to fibronectin for 30
minutes and immunostained with anti-4.1B (A, B), anti-4.1G (C, D), and anti-4.1N
(E, F) antibodies. 4.1B (arrows in A) and 4.1G (arrows in C, D) co-localized with
paxillin in adhesions. Band 4.1N did not co-localize with paxillin, rather it colocalized with DAPI, a nucleus label (E, F). 4.1B-/- astrocytes were still able to form
adhesions, as demonstrated with paxillin-positive contacts (arrows in B).

No

differences in localization patterns of 4.1G and 4.1N were seen between wild type
(C, E) and 4.1B-/- (D, F) astrocytes. Images are shown at 400x.
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Interestingly, Bands 4.1B, 4.1G, and 4.1N became more diffusely expressed
24 hours after fibronectin adhesion (Figure 25A-C). Further analysis of the protein
expression revealed that Band 4.1B and Band 4.1G became concentrated at cellcell junctions when cells contacted with one another (Figure 25D, E). However,
Band 4.1N remained diffusely expressed even when cell-cell contacts were formed
(Figure 25F). No differences in the localization patterns of Band 4.1G (Figure 25B,
E) and Band 4.1N (Figure 25 C, F) were seen between wild type and 4.1B-/astrocytes.
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Figure 25. Protein 4.1 sub-cellular localization changes as cell-cell contacts are
formed.
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Figure 25. Protein 4.1 sub-cellular localization changes as cell-cell contacts
are formed.
A-F: The expression of 4.1 proteins was examined 24 hours after astrocyte
adhesion to fibronectin. 4.1B (A), 4.1G (B), and 4.1N (C) became diffusely
expressed at 24 hours. Interestingly, 4.1B (D) and 4.1G (E) became concentrated at
cell-cell junctions when cells contacted with one another, although 4.1N remained
diffusely expressed (F). No differences in the localization patterns of 4.1G (B, E)
and 4.1N (C, F) were seen between wild type and 4.1B-/- astrocytes. Images are
shown at 400x.
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4.2.3. Band 4.1B and β1 integrin co-localize to cell-ECM contact sites.
β1 integrin is a major fibronectin receptor. Given the importance of integrins in cellECM adhesion, the localization patterns of Band 4.1B and β1 integrin were
compared in astrocytes adhering to fibronectin. Wild type astrocytes were allowed
to interact with fibronectin for 1 hour or 24 hours. The adherent cells were then
immunolabeled with anti-4.1B, anti-β1, and anti-paxillin antibodies. In early hours,
both Band 4.1B (Figure 26A) and β1 integrin (Figure 26B) co-localized with paxillin,
indicating their localizations at the adhesion sites. However, after 24 hours, Band
4.1B became diffusely expressed (Figure 26C) whereas β1 integrin remained colocalized with paxillin (Figure 26D). As evident by the presence of paxillin-labeled
focal contacts, the appearance of focal adhesions did not change when Band 4.1B
was absent from the adhesion sites (Figure 26C).
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Figure 26. Band 4.1B and β1 integrin localize to adhesions during early stages of
cell adhesion and spreading.
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Figure 26. Band 4.1B and β1 integrin localize to adhesions during early stages
of cell adhesion and spreading.
A-D: Wild type and 4.1B-/- astrocytes adhering to fibronectin were labeled with anti4.1B (A, C), anti-β1 (B, D), and anti-paxillin (A-D) antibodies. At one hour, Band
4.1B (arrows in A) and β1 integrin (arrows in B) co-localized with paxillin, indicating
their localization to the adhesion sites. At 24 hours, however, Band 4.1B became
diffusely expressed (C) whereas β1 integrin remained co-localized with paxillin (D
arrows). Paxillin-labeled adhesion sites were still present when Band 4.1B was no
longer expressed in the adhesion sites (arrows in C). Images shown at 400x.
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Based on the co-localization of both Band 4.1B and β1 integrin with paxillin,
we postulated that these two proteins might co-localize, as well. Therefore,
fibronectin-adherent wild type and 4.1B-/- astrocytes were immunostained with anti4.1B and anti-β1 antibodies. As expected, Band 4.1B and β1 integrin co-localized
during early spreading (Figure 27A), but did not stay co-localized at 2 hours (Figure
27C). The localization of β1 integrin to adhesions was not altered by the changes in
Band 4.1B expression (Figure 27 A, C). Furthermore, the lack of Band 4.1B
expression in 4.1B-/- astrocytes did not affect β1 integrin’s localization to focal
adhesions (Figure 27B, D).
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Figure 27. Band 4.1B and β1 integrin co-localize during early cell spreading.
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Figure 27. Band 4.1B and β1 integrin co-localize during early cell spreading.
A-D: Fibronectin-adherent wild type (A, C) and 4.1B-/- (B, D) astrocytes were
immunostained with anti-4.1B and anti-β1 antibodies. Band 4.1B and β1 integrin colocalized one hour after fibronectin adhesion (arrows in A), but did not stay colocalized at 2 hours (C). β1 localization to focal adhesions was unaffected by loss of
Band 4.1B expression in adhesions (arrows in C). The absence of Band 4.1B
expression in 4.1B-/- astrocytes did not influence β1 integrin’s localization to focal
adhesions (arrows in B, D). Images are shown at 400x.
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In vivo expression of Band 4.1B and β1 integrin was also determined using
E11.5 wild type embryos. Fresh-frozen embryo sections were immunofluorescently
labeled with anti-4.1B and anti-β1 antibodies. Band 4.1B and β1 integrin colocalized to the plasma membrane at regions of cell-cell contact, especially in the
neural tube (Figure 28). In addition, β1 integrin was strongly expressed in blood
vessels (arrows in Figure 28).
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Figure 28. Band 4.1B and β1 integrin co-localize in the neuroepithelium.
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Figure 28. Band 4.1B and β1 integrin co-localize in the neuroepithelium.
In vivo expression of Band 4.1B and β1 integrin was determined in E11.5 wild type
embryos. Fresh-frozen embryo sections were immunofluorescently labeled with
anti-4.1B and anti-β1 integrin antibodies and IgG controls. Band 4.1B and β1
integrin co-localized to the plasma membrane at regions of cell-cell contact. β1
integrin, but not Band 4.1B, was also strongly expressed in blood vessels (arrows).
Images are shown at 400x.
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4.2.4. Band 4.1B is not necessary for cell adhesion to the ECM.
The localization of Band 4.1B to cell-ECM contacts led to the examination of
Band 4.1B’s role in cell adhesion. Wild type and 4.1B-/- astrocytes were plated on a
96-well plate coated with laminin, an ECM molecule for 30 minutes. The cells
adhering to laminin were stained with crystal violet. The crystal violet-positive cells
were quantified using an ELISA reader. The numbers of wild type and 4.1B-/adherent cells were not significantly different (Figure 29A), indicating Band 4.1B
does not influence initial adhesion of cells to the ECM.
Morphologies of wild type and 4.1B-/- astrocytes were also examined after
adhesion to laminin. Again, these astrocytes were plated onto laminin-coated
coverslips for 30 minutes and labeled with phalloidin, a cytoskeleton marker. Careful
examination of the attached cells revealed that the morphologies of wild type and
4.1B-/- astrocytes after initial adhesion were not significantly different from one
another (Figure 29B).
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Figure 29. Band 4.1B is not necessary for cell adhesion to the ECM.
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Figure 29. Band 4.1B is not necessary for cell adhesion to the ECM.
A: Wild type and 4.1B-/- astrocytes were plated on a 96-well plate coated with
laminin for 30 minutes. After staining the adherent cells with crystal violet, the
differences in cell adhesion in these cells were quantified. The numbers of wild type
and 4.1B-/- adherent cells were not significantly different (p>0.05). B: Wild type and
4.1B-/- astrocytes were also examined for their morphologies after a brief interaction
with laminin. The cells were stained with phalloidin, a cytoskeleton marker. The
morphologies of wild type and 4.1B-/- astrocytes were not significantly different from
one another. Images are shown at 400x.
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4.2.5. The FERM domain of Band 4.1B enhances cell spreading on fibronectin.
The FERM domain is thought to be crucial for mediating cell spreading. To
determine the effects of the 4.1B FERM domain on cell spreading, COS7 cells were
transiently transfected with myc-tagged 4.1B FERM, full length 4.1B, and LacZ
constructs (McCarty et al., 2005a) for 48 hours. These cells were allowed to adhere
to fibronectin and stained with an anti-myc antibody. The areas of cell spreading
were quantified by a software analysis of captured images of myc-labeled cells.
Strikingly, COS7 cells that were transfected with 4.1B FERM and full length 4.1B
constructs displayed enhanced spreading on fibronectin (Figure 30B, C), compared
to the cells transfected with LacZ control (Figure 30A). These spreading differences
were statistically significant (p<0.01) (Figure 30D). A similar analysis using
vitronectin adherent cells did not show spreading differences in cells transfected
with these constructs (data not shown).
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Figure 30. The FERM domain of Band 4.1B enhances cell spreading on fibronectin.
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Figure 30. The FERM domain of Band 4.1B enhances cell spreading on
fibronectin.
A-C: COS7 cells were transiently transfected with myc-tagged LacZ (A), 4.1B FERM
(B), and full length 4.1B (C) constructs for 48 hours and stained with an anti-myc
antibody. Images are shown at 400x. 4.1B FERM (B) and full length 4.1B (C)
transfected cells displayed enhanced spreading on fibronectin, compared to the
LacZ control (A). D: The areas of cell spreading were quantified by a software
analysis of captured images of the myc-labeled cells. 4.1B FERM and full length
4.1B transfected cells showed statistically significant (*p<0.01) enhancement of
spreading, compared to the LacZ control.
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Since the increased spreading in 4.1B transfected cells was only observed in
cells interacting with fibronectin, it was speculated that Band 4.1B, especially the
Band 4.1B FERM domain, promotes cell spreading mediated by β1 integrin.
Therefore, cells that were transfected with the 4.1B FERM, full length 4.1B, and
LacZ constructs were treated with a β1 integrin blocking antibody prior to being
plated on fibronectin. Again, cells transfected with 4.1B FERM (Figure 31B) and full
length 4.1B (Figure 31C) constructs showed enhanced spreading on fibronectin
without blocking, in comparison to the LacZ control (Figure 31A). However, the
enhanced cell spreading in these cells was abolished after blocking β1 (Figure 31DF).
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Figure 31. Band 4.1B FERM domain promotes cell spreading mediated by β1
integrin.
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Figure 31. Band 4.1B FERM domain promotes cell spreading mediated by β1
integrin.
A-F: 293T cells that were transfected with 4.1B FERM, full length 4.1B, and LacZ
constructs were treated with a β1 integrin blocking antibody P5D2 prior to being
plated on fibronectin. Again, cells transfected with 4.1B FERM (B) and full length
4.1B (C) constructs showed enhanced spreading on fibronectin, in comparison to
the LacZ control (A). P5D2 blocked the increased spreading in these cells (D-F).
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4.3. Discussion
The functional roles for Band 4.1B in the brain, and especially in astrocytes,
have not been identified. This study was the first to show time-dependant
localization changes of Band 4.1B expression in astrocytes and to implicate the
involvement of Band 4.1B in cell adhesion and spreading. Here, the FERM domain
of Band 4.1B was shown to promote β1 integrin-mediated early cell spreading by
localizing to β1 integrin-rich cell-ECM adhesion sites.
Band 4.1B has been previously shown to localize to the plasma membrane at
regions of direct cell-cell contact (Parra et al., 2000). Given the subcellular
expression, Band 4.1B has been speculated to be involved in cell-cell, cell-ECM
interactions. Similar to the previous report, Band 4.1B in astrocytes also localizes to
the plasma membrane when cell-cell contacts are formed. However, it is important
to note that the localization patterns of Band 4.1B change throughout the stages of
cell adhesion and spreading. Interestingly, Band 4.1B localizes to paxillin-labeled
adhesions only during early cell spreading, but becomes diffusely expressed in later
stages of cell spreading. Although the expression of Band 4.1B is diffuse in sparse
cultures of astrocytes, Band 4.1B becomes concentrated at cell-cell junctions when
cells form contacts with one another. No differences in the protein expression of
Band 4.1B were observed between sparse and confluent cultures of astrocytes, as
demonstrated by immunoblot analysis (data not shown). Therefore, the changes in
localization of Band 4.1B are not accompanied by the changes in protein
expression. These novel findings suggest that Band 4.1B may be important for early
adhesion assembly and signaling, but dispensable for the maintenance of focal
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adhesions. In addition, Band 4.1B is likely to mediate cell-cell interactions once
focal adhesions are well established and cells begin to form contacts with each
other. Collectively, the data from this study demonstrate stage-dependant changes
in Band 4.1B localization in astrocytes and suggest multiple intracellular roles for
Band 4.1B in cell adhesion and signaling.
Interestingly, these unique changes in Band 4.1B localization are seen in
astrocytes adherent to fibronectin, an ECM protein ligand for β1 integrins. β1
integrin binds multiple α subunits (Baczyk et al., 2010; Takada et al., 2007; Hynes,
2002). β1 integrin has been shown to participate in various cellular events, including
cell-ECM adhesion and cell spreading (Harburger and Calderwood, 2009). As
shown in this study, astrocytes express multiple β1 containing integrins, such as
α2β1, α3β1, α5β1, α6β1, and αVβ1. Therefore, it was speculated that β1 integrin is
an important regulator of astrocyte adhesion and signaling. Similar to Band 4.1B, β1
integrin localizes to paxillin-containing adhesions during initial cell spreading.
However, unlike Band 4.1B, β1 integrin remains in focal adhesions even after cells
make initial contact with the ECM. These findings suggest that β1 integrin is
important not only for early adhesion formation, but also for maintenance of focal
adhesions.
Co-localization of Band 4.1B and β1 integrin occur only during early stages
of cell spreading on fibronectin. This suggests that their interactions are likely to be
important for early adhesion formation and/or stabilization. Cell-ECM adhesion is
the critical first step for various cellular events. Talin, a member of the protein 4.1
superfamily, has been reported to regulate cell adhesion and spreading through its
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interaction with β1 integrin (Zhang et al., 2008). Talin mediates focal adhesion
formation and organization by activating β1 integrin, bridging the integrin with the
actin cytoskeleton, and modulating intracellular signaling (Zhang et al., 2008). Given
the similarities between talin and Band 4.1B, Band 4.1B may perform redundant
functions in astrocytes. Alternatively, Band 4.1B may be important for establishing
cell adhesion and spreading events before talin takes over regulating these
processes. In fact, talin is not involved in initial cell spreading, including primary
adhesion formation and early cell-edge extension (Zhang et al., 2008). Therefore,
the interactions between β1 integrin and Band 4.1B in the early stage of cell
spreading may be an initiating event for adhesion formation and membrane
extension.
The exact functions of Band 4.1B in β1-rich adhesions have yet to be
determined. One possibility is that Band 4.1B may be necessary for proper
localization of β1 integrin to newly forming adhesions through their physical
interactions. Alternatively, Band 4.1B may influence intracellular signaling regulated
by β1 integrin. In the absence of Band 4.1B, β1 integrin were still detectable in
adhesions. Furthermore, Band 4.1B did not affect initial cell-ECM contact modulated
by β1 integrin. Therefore, Band 4.1B is unlikely to recruit β1 integrin to newly
forming adhesions. Instead, β1 integrin may recruit Band 4.1B to early adhesion
sites for regulating intracellular signaling or the cytoskeleton.
Several FERM containing proteins have been shown to regulate cell
spreading that is a downstream event of integrin-initiated cell adhesion (Gutmann et
al., 1999; Zhang et al., 2008). Based on the data from the present study, Band 4.1B
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also promotes cell spreading. Interestingly, the expression of Band 4.1B FERM
alone is sufficient to increase cell spreading. This indicates that the FERM domain
is responsible for modulating signaling pathways altering cell behavior.
Although Band 4.1B CTD’s interaction with β8 integrin have been studied
(McCarty et al., 2005a), other domains of Band 4.1B have not been explored for
their integrin binding capabilities. Piao and colleagues have suggested interactions
between Band 4.1B and β1 integrin in their prior report (2009). Given that enhanced
spreading was seen in 4.1B FERM-expressing cells on fibronectin, an ECM ligand
for β1 integrin, the FERM domain may be an essential region of Band 4.1B for β1
interaction. Through this interaction, Band 4.1B may participate in β1 integrinmediated intracellular signaling cascades. Abolishment of enhanced cell spreading
with a β1 blocking antibody indirectly shows that Band 4.1B FERM-β1 interaction
induces better cell spreading.
Despite the proposed roles of Band 4.1B in β1-mediated cell adhesion and
signaling, 4.1B-/- astrocytes do not behave differently from wild type astrocytes.
Even in the absence of Band 4.1B, these cells form normal paxillin-positive
adhesions, have β1-containing focal contacts, and display normal cell morphology
and spreading. The lack of differences between wild type and 4.1B-/- cells may be
contributed by other 4.1 proteins playing redundant functions in the absence of
Band 4.1B. Bands 4.1G and 4.1N are highly expressed in 4.1B-/- astrocytes. In
particular, Band 4.1G shares similar expression patterns with Band 4.1B: Band
4.1G localizes to primary adhesions during early spreading and to cell-cell junctions
upon completion of cell spreading. Band 4.1G may take over the functions of Band
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4.1B when Band 4.1B is not present. Clear phenotype differences demonstrated
between Band 4.1B-expressing COS7 cells and untransfected cells that lack
endogenous protein 4.1 expression strongly support this possibility. In this case, it is
still possible that Band 4.1B may play a role in recruitment of β1 integrin to early
adhesions, but this might not be apparent in this study due to the presence of other
4.1 proteins in knockout cells.
In summary, Band 4.1B may be involved in the formation of primary adhesion
and/or intracellular signaling through the interaction between its FERM domain and
β1 integrin during initial cell spreading. However, it is difficult to clearly demonstrate
their functions in these cellular processes due to the presence of other 4.1 proteins
that might play redundant roles. The examination of Band 4.1B in the absence of
other 4.1 proteins using siRNA-mediated approaches would be useful for better
characterization of Band 4.1B’s functional roles.
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Chapter 5. Summary and Future Directions
This study was the first to demonstrate the in vivo and in vitro functions of
Band 4.1B in integrin-mediated cell adhesion and signaling. The key findings of the
present study are as follows:
Specific Aim I:
1. β8 and Band 4.1B are expressed in the embryonic heart (Figures 16, 19).
The expressions of β8 integrin and Band 4.1B were detected in endocardial
cushions of the AV junction and OFT as well as the myocardium.
2. Most mice that are genetically null for β8 integrin and Band 4.1B die by E11.5
(Table 2).
The number of β8-/-;4.1B-/- mice that were born was 60% less than
expected. Although these mice were present in the expected Mendelian ratio
at E10.5, they showed 8% viability at E11.5.
3. β8-/-;4.1B-/- mice that survive until adulthood die of hydrocephalus caused by
intracerebral hemorrhage (Figures 9, 10).
β8-/-;4.1B-/- mice displayed hunched posturing, abnormal gait, and seizure
activity by the third week of their lives and died before P40. The cause of
death was severe hydrocephalus secondary to intracerebral hemorrhage.
Although striking, these phenotypes were similarly observed in β8-/- mice,
suggesting these features were mainly the effects of absent β8 integrin.
4. The defective cardiovascular system contributes to the lethal phenotype of β8-/;4.1B-/- embryos (Figures 11-14).
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Hypovascularity in the yolk sac and embryo proper was the most grossly
noticeable feature of the double mutants. Defective blood vessel formation in
the yolk sac and neural tube was also seen in these embryos.
5. Abnormal morphogenesis of the outflow tract is seen the β8-/-;4.1B-/- heart
(Figures 17, 18).
Hypotrophy of the OFT endocardial cushion with the diminished expression
of multiple neural crest markers and thinning of myocardium were
demonstrated in the double mutants.
6. Neural crest cell migration is impaired in β8-/-;4.1B-/- embryos (Figures 20, 21).
A defective neurofilament network in β8-/-;4.1B-/- embryos was evident by
aberrant projections of the cranial nerve V branches into the pharyngeal
arches and abnormal neurofilament patterning in the trunks.

Functional links between β8 integrin and Band 4.1B in vivo have never been
shown prior to the present study. This study shows cooperative functions for β8
integrin and Band 4.1B in embryonic heart development. Given the importance of
cardiac neural crest cells in OFT formation and similar OFT abnormalities seen in
other mouse models with cardiac neural crest migration defects, β8 integrin and
Band 4.1B are suspected to work together to support neural crest cell migration to
the OFT and possibly other regions of the developing heart. In particular, β8 integrin
and Band 4.1B may contribute to proper migration of neural crest cells by regulating
TGFβ signaling pathways since mice lacking various TGFβ family members share
similar features with the double mutants.
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The exact mechanisms by which β8 integrin and Band 4.1B affect cardiac
morphogenesis are yet to be determined. Selective ablation of these genes in
neural crest cells, especially cardiac neural crest cells, would provide better
understanding of β8-4.1B signaling in cardiac morphogenesis. In addition, the
involvement of Band 4.1B in integrin-mediated TGFβ activation and signaling and
the roles of these signaling cascades in the development of neural crest-derived
structures may be addressed using in vitro approaches. Given the abnormal
neurofilament projections shown in the double knockout embryos, impaired
migration of neural crest cells is strongly suspected. To demonstrate defective
neural crest migration, cells isolated from the double mutants can be utilized for in
vitro migration assays. These cells can also be subject to time-lapse monitoring of
cell movement to understand dynamic regulation of cell migration by β8 integrin and
Band 4.1B. In vitro approaches will also allow rescue experiments to monitor the
reversibility of the abnormal migration phenotype by re-expressing β8 integrin and
Band 4.1B in cells. Furthermore, β8 integrin and Band 4.1B’s regulation of TGFβ
pathways can be studied by examining downstream molecules of TGFβ signaling
cascades, such as SMAD2/3 and 4. By utilizing antibodies against these proteins,
changes in the levels of expression and activation of TGFβ signaling molecules can
be detected in double knockout neural crest cells.
Although β8-/-;4.1B-/- embryos exhibit striking lethal phenotypes, these
phenotypes are partially penetrant. The partial penetrance of lethality in these mice
was attributed to their background strain variation. In many mutant mice, including
knockout mice of β8 integrin and TGFβ’s show strain-dependent phenotypes (Zhu
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et al., 2002; Mobley et al., 2009; Bonyadi et al., 1997). These differences may be
explained by the presence of genetic modifiers in specific strains. Therefore, it
would be worthwhile to investigate potential contributions of genetic modifiers to
cardiac development by backcrossing the double knockout mutants to 129S4 and
C57BL6 backgrounds.
Since impaired OFT is commonly seen in congenital heart disease, β8
integrin and Band 4.1B may be important players in human cardiac morphogenesis.
In DiGeorge syndrome, neural crest cell derived structures, including the OFT and
aortic arch are severely defected (Stoller and Epstein, 2005). β8 integrin and Band
4.1B have not been implicated in human heart diseases. Given the cardiac defects
seen in β8-/-;4.1B-/- embryos, studying the roles of β8 integrin and Band 4.1B in
DiGeorge syndrome and other congenital heart diseases using animal models and
human samples can lead to the discovery of a new therapeutic target.

Specific Aim II:
1. Astrocytes express multiple 4.1 proteins and β1-containing integrins (Figure 22,
23).
Bands 4.1B, 4.1G, and 4.1N as well as α1β1, α2β1, α3β1, α5β1, α6β1, and
αVβ1 integrins were detected in astrocytes.
2. Band 4.1B shows time-dependent changes in its subcellular localization (Figure
24, 25).
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Band 4.1B localized to primary adhesions during early cell spreading.
However, the expression of Band 4.1B was seen in the plasma membrane at
cell-cell junction when cells formed contacts with one another.
3. Band 4.1B and β1 integrin co-localize to the adhesion sites (Figure 26, 27).
Band 4.1B and β1 integrin co-localized to paxillin-labeled adhesions during
early spreading. However, Band 4.1B became diffusely expressed whereas
β1 integrin remained co-localized with paxillin in late stages of cell spreading.
4. Band 4.1B is not necessary for cell adhesion to the ECM (Figure 29).
Astrocytes that lack Band 4.1B adhere to laminin without any differences
from wild type cells. In addition, the morphologies of wild type and 4.1B-/astrocytes after initial adhesion were not significantly different from one
another.
5. The FERM domain of Band 4.1B enhances β1 integrin-mediated cell spreading
(Figure 30, 31).
Increased cell spreading was demonstrated in cells expressing 4.1B FERM
and full-length 4.1B constructs. However, the enhanced spreading in these
cells was abolished by treating the cells with a β1 blocking antibody.

This study was the first to demonstrate the localization changes of Band 4.1B
during cell spreading and to implicate the involvement of Band 4.1B in β1-mediated
cell adhesion and spreading. These novel findings indicate that Band 4.1B may be
important for early adhesion assembly and signaling, but dispensable for the
maintenance of focal adhesions. It is possible that physical interactions between
Band 4.1B and β1 integrin may be necessary for proper localization of β1 integrin to
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newly forming adhesions. Alternatively, Band 4.1B may function as a downstream
signaling molecule of β1 integrin.
In spite of the proposed roles of Band 4.1B in β1-mediated cell adhesion and
signaling, the lack of differences between wild type and 4.1B-/- cells made it difficult
to demonstrate the exact roles of Band 4.1B in vitro. The presence of redundant
functions among 4.1 proteins could not be ruled out in this study. Therefore, it would
be critical to examine Band 4.1B’s functions in the absence of other 4.1 proteins
using siRNA-mediated approaches. As demonstrated here, Bands 4.1G and 4.1N
are highly expressed in astrocytes, although their functions in these cells have not
been established. Given their subcellular localizations and conserved FERM
domain that share sequence homology with Band 4.1B, other 4.1 proteins may play
similar roles in cell adhesion and signaling mediated by integrins. Especially, Band
4.1G demonstrated similar sub-cellular localization as Band 4.1B. Therefore, limiting
Band 4.1G’s expression in early adhesions by silencing Band 4.1G via RNAimediated approaches may produce significant disruption in cell adhesion and
spreading in cells lacking Band 4.1B. Although Band 4.1N did not localize to cell
adhesions in astrocytes, it may become an important regulator of cell adhesion and
signaling when Bands 4.1B and 4.1G are both absent. It would be interesting to
study if Band 4.1N’s localization patterns change in the absence of other 4.1
proteins and if silencing Band 4.1N negatively affects cell adhesion and signaling
when Bands 4.1B and 4.1G are not present.

128

In addition, subtle changes in adhesion formation during early cell spreading
would be difficult to be shown by observing cell spreading at fixed time intervals.
Since Band 4.1B’s expression in adhesions is time-dependant, its regulation of cell
adhesion and spreading may also be time sensitive and limited to certain stages of
cell spreading. Continuous monitoring of cell adhesion and spreading, therefore,
would provide better understanding of time-dependent changes in adhesion
formation and organization and cell spreading. Time-lapse monitoring of adhesion
assembly/disassembly and cell spreading can be accomplished by transfecting cells
with fluorescently labeled proteins and monitoring the movements of these proteins
in the cells. Given the co-localizations of Band 4.1B, β1 integrin, and paxillin at the
adhesion sites, monitoring dynamic cellular changes using cells transfected with
fluorescently-labeled Band 4.1B, β1 integrin, and paxillin would be a useful first step
for understanding their roles in cell adhesion and spreading.

One possible mechanism by which Band 4.1B is involved in cell adhesion
and signaling is functioning as a downstream adaptor of β1 and other integrins in
early adhesions. Adhesions are the sites for sequestering proteins that are
important for intracellular signaling (Brown et al., 2005). Many adaptor and signaling
proteins play important roles in connecting integrins and the actin cytoskeleton
(Legate et al., 2009; Zhang et al., 2008; Cram et al., 2003). Band 4.1B is also a
known cytoskeletal adaptor protein that is thought to bind to the actin cytoskeleton
via its SABD (Sun et al., 2002). Therefore, Band 4.1B may function as a link
between integrins and the actin cytoskeleton. It may also act as a binding partner of
other molecules in an adhesion complex, sequestering these proteins for further
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intracellular signaling. Thus, the absence of Band 4.1B in cells may influence the
actin cytoskeleton dynamics and/or localization of other adhesion proteins.
Examining the actin organization and other known integrin/actin binding proteins in
adhesions in wild type and 4.1B-/- cells using immunohistochemical approaches
would provide insights into the involvement of Band 4.1B in adhesion complex
regulation.

Given that enhanced cell spreading mediated by Band 4.1B was observed
only on fibronectin, a major ECM ligand for β1 integrin, and this effect was
abolished by the use of a β1 integrin blocking antibody, Band 4.1B was thought to
modulate cell spreading mediated by β1 integrin. Although co-localization of Band
4.1B and β1 integrin in vitro and in vivo suggests that Band 4.1B and β1 integrin are
likely to interact with one another, demonstrating direct interactions between Band
4.1B, and β1 integrin by co-immunoprecipitation would further emphasize the
importance of Band 4.1B in β1 integrin signaling. Examining endogenous
interactions between these two proteins would be the best way to demonstrate their
binding. Since these proteins were shown to co-localize in early adhesions, lysates
made from cells attached to fibronectin for a brief period of time can be used for
displaying the endogenous interaction. However, the transient interactions between
Band 4.1B and β1 integrin may make the co-immunoprecipitation difficult to be
performed, given the time-dependent changes in Band 4.1B localization. Another
way would be to utilize Band 4.1B and β1 integrin constructs and monitor for
exogenous interactions of these proteins. Given the importance of the talin FERM
domain and the β cytoplasmic tails in talin-integrin interactions, the Band 4.1B
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FERM domain that is overexpressed in cells can be allowed to bind to β1
cytoplasmic tail that is attached to a resin.

This study demonstrated several crucial in vivo and in vitro functions for
Band 4.1B in integrin-mediated cell adhesion and signaling. However, the
mechanisms by which Band 4.1B is involved in these cellular events still need to be
determined. The knowledge obtained from the present study would provide a solid
foundation for further analysis of Band 4.1B’s roles. The proposed future studies
would strengthen our understanding of the functions for Band 4.1B in integrinmediated adhesion and signaling.
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